2	B-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
was	O
obtained	O
from	O
the	O
appropriate	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloropyrimidine	I-IUPAC
derivative	B-MODIFIER
by	O
alkaline	O
hydrolysis	O
and	O
ester	O
cleavage	O
.	O
These	O
results	O
indicate	O
that	O
substantial	O
modification	O
of	O
the	O
framework	O
of	O
peptide	O
-	O
based	O
siderophores	O
can	O
be	O
tolerated	O
by	O
microbial	O
iron	O
-	O
transport	O
systems	O
.	O
Of	O
the	O
alkyl	O
-	O
substituted	O
1	O
-	O
position	O
analogs	O
of	O
oxytocin	O
studied	O
so	O
far	O
,	O
[	B-IUPAC
1	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
,	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
pentamethylenepropionic	I-IUPAC
acid	I-IUPAC
]	I-IUPAC
oxytocin	I-IUPAC
is	O
the	O
most	O
potent	O
antioxytocic	O
agent	O
.	O
These	O
compounds	O
were	O
radiolabeled	O
with	O
fluorine	O
-	O
18	O
,	O
and	O
their	O
biological	O
properties	O
were	O
evaluated	O
in	O
rats	O
and	O
compared	O
with	O
those	O
of	O
[	O
11C	O
]	O
carbonyl	O
WAY	O
100635	O
(	O
[	O
carbonyl	O
-	O
11C	O
]	O
4a	O
)	O
.	O
ABPA	O
proved	O
to	O
be	O
equipotent	O
with	O
AMPA	O
both	O
as	O
an	O
inhibitor	O
of	O
AMPA	O
binding	O
and	O
as	O
a	O
neuronal	O
excitant	O
.	O
The	O
tetrahydropyridine	O
analog	O
of	O
10	O
,	O
compound	O
13	O
,	O
showed	O
a	O
markedly	O
lower	O
receptor	O
affinity	O
(	O
IC50	O
=	O
32	O
+	O
/	O
-	O
10	O
microM	O
)	O
and	O
apparently	O
a	O
lower	O
relative	O
efficacy	O
than	O
10	O
.	O
Methotrexate	O
poly	O
(	O
gamma	O
-	O
L	O
-	O
glutamate	O
)	O
s	O
bearing	O
two	O
and	O
three	O
glutamate	O
units	O
above	O
that	O
present	O
in	O
methotrexate	O
have	O
been	O
synthesized	O
by	O
extension	O
of	O
a	O
previously	O
described	O
route	O
used	O
to	O
synthesize	O
the	O
lower	O
conjugate	O
bearing	O
one	O
added	O
glutamate	O
unit	O
.	O
Therefore	O
,	O
the	O
interaction	O
of	O
the	O
drug	O
with	O
the	O
binding	O
site	O
,	O
responsible	O
for	O
its	O
biological	O
activity	O
,	O
appears	O
to	O
be	O
governed	O
by	O
a	O
dynamic	O
process	O
.	O
Compound	O
5e	O
showed	O
high	O
affinity	O
for	O
rat	O
A	O
(	O
2A	O
)	O
AR	O
(	O
K	O
(	O
i	O
)	O
=	O
8	O
nM	O
)	O
,	O
human	O
recombinant	O
A	O
(	O
2A	O
)	O
AR	O
(	O
K	O
(	O
i	O
)	O
=	O
5	O
nM	O
)	O
,	O
and	O
human	O
native	O
A	O
(	O
2A	O
)	O
AR	O
(	O
K	O
(	O
i	O
)	O
=	O
15	O
nM	O
)	O
and	O
was	O
highly	O
selective	O
versus	O
rat	O
A	O
(	O
1	O
)	O
AR	O
(	O
110	O
-	O
fold	O
)	O
,	O
human	O
recombinant	O
A	O
(	O
2A	O
)	O
AR	O
(	O
500	O
-	O
fold	O
)	O
,	O
human	O
A	O
(	O
2B	O
)	O
AR	O
(	O
&	O
gt	O
;	O
2000	O
-	O
fold	O
)	O
,	O
and	O
human	O
A	O
(	O
3	O
)	O
AR	O
(	O
&	O
gt	O
;	O
2000	O
-	O
fold	O
)	O
.	O
Furthermore	O
,	O
when	O
9a	O
was	O
given	O
twice	O
daily	O
at	O
a	O
dosage	O
of	O
40	O
mg	O
/	O
kg	O
for	O
6	O
consecutive	O
days	O
,	O
a	O
T	O
/	O
C	O
value	O
of	O
165	O
was	O
obtained	O
and	O
60%	O
of	O
the	O
mice	O
were	O
60	O
-	O
day	O
long	O
-	O
term	O
survivors	O
.	O
b	O
.	O
Of	O
the	O
20	O
compounds	O
evaluated	O
,	O
six	O
exhibited	O
biologically	O
significant	O
anti	O
-	O
L1210	O
activity	O
in	O
BD2F1	O
mice	O
and	O
reduced	O
body	O
burdens	O
of	O
viable	O
L1210	O
cells	O
more	O
than	O
90-97%	O
by	O
single	O
treatment	O
.	O
4,5,6,7	B-IUPAC
-	I-IUPAC
Tetrahydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5,1	I-IUPAC
-	I-IUPAC
jk	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
benzodiazepin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
TIBO	O
)	O
,	O
1	O
,	O
have	O
been	O
shown	O
to	O
significantly	O
inhibit	O
HIV	O
-	O
1	O
replication	O
in	O
vitro	O
by	O
interfering	O
with	O
the	O
virus	O
's	O
reverse	O
transcriptase	O
enzyme	O
.	O
A	O
more	O
specific	O
process	O
was	O
used	O
for	O
the	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
compound	B-MODIFIER
,	O
i.e.	O
,	O
nucleophilic	O
displacement	O
of	O
nitrite	O
from	O
methyl	B-IUPAC
5	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylate	I-IUPAC
by	O
sodioformanilide	O
and	O
subsequent	O
hydrolysis	O
.	O
As	O
an	O
inhibitor	O
of	O
TS	O
from	O
H35F	O
/	O
F	O
cells	O
,	O
4	O
gave	O
an	O
IC50	O
value	O
showing	O
it	O
to	O
be	O
approximately	O
6	O
-	O
fold	O
less	O
inhibitory	O
than	O
PDDF	O
(	O
90	O
nM	O
for	O
4	O
vs	O
14	O
nM	O
for	O
PDDF	O
)	O
.	O
2beta	O
-	O
(	O
R	O
)	O
-	O
Carbo	O
-	O
1	O
-	O
fluoro	O
-	O
2	O
-	O
propoxy	O
-	O
3beta	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
tro	O
pane	O
(	O
(	O
R	O
)	O
-	O
FIPCT	O
,	O
R	O
-	O
6	O
)	O
and	O
2beta	B-IUPAC
-	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carbo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
tro	I-IUPAC
pane	I-IUPAC
(	O
(	O
S	O
)	O
-	O
FIPCT	O
,	O
S	O
-	O
6	O
)	O
were	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
selectivity	O
and	O
specificity	O
.	O
Compound	O
4	O
was	O
found	O
to	O
be	O
the	O
most	O
active	O
agent	O
of	O
this	O
series	O
of	O
compounds	O
.	O
The	O
symmetrical	O
diamidines	O
14a	O
,	O
b	O
were	O
synthesized	O
through	O
the	O
corresponding	O
bis	B-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetoxyamidoxime	I-IUPAC
followed	O
by	O
hydrogenation	O
.	O
New	O
histamine	O
derivatives	O
characterized	O
by	O
a	O
(	O
substituted	O
)	O
aryl	O
,	O
heteroaryl	O
,	O
benzyl	O
,	O
or	O
heteroarylmethyl	O
substituent	O
in	O
the	O
C2	O
position	O
of	O
the	O
imidazole	O
ring	O
have	O
been	O
prepared	O
from	O
appropriate	O
imidates	O
or	O
amidines	O
,	O
respectively	O
,	O
and	O
2	B-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phthalimido	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
acetate	I-IUPAC
(	O
1	O
)	O
.	O
A	O
composite	O
hydrogen	O
-	O
bonding	O
environment	O
has	O
been	O
constructed	O
for	O
the	O
TRH	O
analogue	O
system	O
and	O
examined	O
for	O
its	O
inference	O
with	O
respect	O
to	O
receptor	O
binding	O
.	O
Derivatives	O
of	O
the	O
nonselective	O
excitatory	O
amino	O
acid	O
antagonist	O
kynurenic	O
acid	O
(	O
4	B-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydroquinoline	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
,	O
1	O
)	O
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
in	O
vitro	O
antagonist	O
activity	O
at	O
the	O
excitatory	O
amino	O
acid	O
receptors	O
sensitive	O
to	O
N	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
aspartic	I-IUPAC
acid	I-IUPAC
(	O
NMDA	O
)	O
,	O
quisqualic	O
acid	O
(	O
QUIS	O
or	O
AMPA	O
)	O
,	O
and	O
kainic	O
acid	O
(	O
KA	O
)	O
.	O
Compound	O
7g	O
turned	O
out	O
to	O
be	O
a	O
very	O
weak	O
AMPA	O
receptor	O
agonist	O
(	O
IC50	O
=	O
12	O
+	O
/	O
-	O
0.7	O
microM	O
;	O
EC50	O
=	O
160	O
+	O
/	O
-	O
15	O
microM	O
)	O
.	O
The	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
and	O
the	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
isomer	B-MODIFIER
possessed	O
similar	O
potencies	O
as	O
D	O
-	O
1	O
antagonists	O
.	O
The	O
other	O
assay	O
measured	O
retinoid	O
-	O
induced	O
differentiation	O
of	O
the	O
human	O
myoloid	O
leukemia	O
cell	O
line	O
HL	O
-	O
60	O
.	O
In	O
general	O
,	O
the	O
compounds	O
structurally	O
related	O
to	O
BTCP	O
exhibited	O
greater	O
selectivity	O
for	O
sites	O
labeled	O
by	O
[	O
3H	O
]	O
BTCP	O
.	O
The	O
most	O
potent	O
broad	O
spectrum	O
agent	O
in	O
the	O
NCI	O
cell	O
panel	O
was	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorobenzothiazole	I-IUPAC
(	O
10h	O
)	O
which	O
,	O
unlike	O
the	O
6	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
isomer	B-MODIFIER
(	O
10d	O
)	O
,	O
produces	O
no	O
exportable	O
metabolites	O
in	O
the	O
presence	O
of	O
sensitive	O
MCF	O
-	O
7	O
cells	O
.	O
Treatment	O
of	O
spermine	O
with	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dimethoxybenzoyl	I-IUPAC
)	I-IUPAC
thiazol	I-IUPAC
-	I-IUPAC
idine	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thione	I-IUPAC
(	O
1	O
)	O
(	O
molar	O
ratio	O
2	O
:	O
1	O
)	O
gave	O
1,14	B-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
dimethoxybenzoyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,5,10,14	I-IUPAC
-	I-IUPAC
tetraazatetradecane	I-IUPAC
(	O
2	O
,	O
DiCAM	O
-	O
spermine	O
)	O
in	O
80%	O
yield	O
.	O
CNS	O
-	O
stimulating	O
activity	O
was	O
also	O
evaluated	O
by	O
examining	O
the	O
promotional	O
effect	O
on	O
the	O
recovery	O
from	O
cerebral	O
concussion	O
induced	O
coma	O
in	O
mice	O
.	O
Regeneration	O
of	O
the	O
5,6	O
-	O
olefinic	O
bond	O
to	O
give	O
AZT	O
,	O
upon	O
incubation	O
of	O
the	O
5	B-IUPAC
-	I-IUPAC
halo	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
5,6	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
compounds	B-MODIFIER
with	O
glutathione	O
,	O
mouse	O
blood	O
,	O
or	O
mouse	O
liver	O
homogenate	O
,	O
was	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
5	B-IUPAC
-	I-IUPAC
halo	I-IUPAC
substituent	B-MODIFIER
(	O
I	O
&	O
gt	O
;	O
Br	O
)	O
.	O
Structure	O
-	O
-	O
activity	O
relationships	O
for	O
4	B-IUPAC
-	I-IUPAC
[	I-IUPAC
2p	I-IUPAC
(	I-IUPAC
arylmethyl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
piperidines	I-IUPAC
are	O
generally	O
similar	O
to	O
the	O
profile	O
established	O
for	O
3	B-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidines	I-IUPAC
]	I-IUPAC
.	O
This	O
suggests	O
that	O
new	O
,	O
more	O
stable	O
and	O
selective	O
nucleotide	O
agonists	O
may	O
be	O
designed	O
on	O
the	O
basis	O
of	O
the	O
(	O
N	O
)	O
-	O
conformation	O
,	O
which	O
greatly	O
enhanced	O
potency	O
at	O
P2Y	O
(	O
1	O
)	O
receptors	O
.	O
The	O
MAP	O
facility	O
within	O
the	O
Chem	O
-	O
X	O
molecular	O
modeling	O
program	O
was	O
then	O
used	O
to	O
calculate	O
the	O
region	O
of	O
steric	O
interference	O
(	O
termed	O
the	O
receptor	O
essential	O
volume	O
,	O
REV	O
)	O
from	O
these	O
accessible	O
conformers	O
.	O
Nonclassical	O
antifolates	O
,	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
substituted	I-IUPAC
-	I-IUPAC
furo	I-IUPAC
[	I-IUPAC
2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
3-12	O
with	O
bridge	O
region	O
variations	O
of	O
C8	O
-	O
S9	O
,	O
C8	O
-	O
N9	O
,	O
and	O
C8	O
-	O
O9	O
and	O
1	B-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
,	O
2	B-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
,	O
2	B-IUPAC
-	I-IUPAC
phenoxyphenyl	I-IUPAC
,	O
4	B-IUPAC
-	I-IUPAC
phenoxyphenyl	I-IUPAC
,	O
and	O
2	B-IUPAC
-	I-IUPAC
biphenyl	I-IUPAC
side	B-MODIFIER
chains	I-MODIFIER
were	O
synthesized	O
as	O
phenyl	O
ring	O
appended	O
analogues	O
of	O
previously	O
reported	O
2	B-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
anilinomethyl	I-IUPAC
)	I-IUPAC
furo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
.	O
Novel	O
requisite	O
heterocycles	B-MODIFIER
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
7a	O
)	O
and	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
7b	O
)	O
were	O
prepared	O
by	O
halogenating	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
5	O
)	O
.	O
New	O
boron	O
-	O
containing	O
polyamine	O
have	O
been	O
synthesized	O
:	O
(	B-IUPAC
aminoalkylamine	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
azanonaborane	I-IUPAC
(	O
11	O
)	O
derivatives	B-MODIFIER
[	O
H	O
(	O
2	O
)	O
N	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
n	O
)	O
H	O
(	O
2	O
)	O
NB	O
(	O
8	O
)	O
H	O
(	O
11	O
)	O
NH	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
n	O
)	O
NH	O
(	O
2	O
)	O
]	O
,	O
where	O
n	O
=	O
4-6	O
and	O
12	O
,	O
and	O
[	O
H	O
(	O
2	O
)	O
N	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
H	O
(	O
2	O
)	O
NB	O
(	O
8	O
)	O
H	O
(	O
11	O
)	O
NH	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
4	O
)	O
NH	O
(	O
2	O
)	O
]	O
.	O
The	O
rat	O
antipressor	O
potency	O
of	O
[	B-IUPAC
1	I-IUPAC
-	I-IUPAC
deaminopenicillamine	I-IUPAC
]	I-IUPAC
oxytocin	I-IUPAC
was	O
also	O
determined	O
in	O
this	O
study	O
:	O
pA2	O
=	O
6.27	O
.	O
The	O
tested	O
compounds	O
showed	O
high	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
1A	O
)	O
and	O
alpha	O
(	O
1	O
)	O
receptors	O
(	O
K	O
(	O
i	O
)	O
=	O
1.1-87	O
and	O
10-62	O
nM	O
,	O
respectively	O
)	O
and	O
moderate	O
to	O
low	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
2A	O
)	O
(	O
K	O
(	O
i	O
)	O
=	O
56-881	O
nM	O
)	O
and	O
D	O
(	O
2	O
)	O
receptors	O
(	O
K	O
(	O
i	O
)	O
=	O
94-1245	O
nM	O
)	O
.	O
An	O
alternate	O
procedure	O
which	O
consisted	O
of	O
reacting	O
4	B-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
formylpyridine	I-IUPAC
ethylene	I-IUPAC
acetal	I-IUPAC
with	O
various	O
amines	O
,	O
followed	O
by	O
hydrolysis	O
and	O
reaction	O
with	O
thiosemicarbazide	O
,	O
was	O
also	O
employed	O
.	O
8	O
was	O
shown	O
to	O
be	O
photochemically	O
active	O
and	O
is	O
a	O
potential	O
photoaffinity	O
label	O
for	O
the	O
recognition	O
site	O
of	O
the	O
AMPA	O
receptors	O
.	O
Compounds	O
7a	O
-	O
c	O
failed	O
to	O
increase	O
the	O
life	O
span	O
of	O
mice	O
infected	O
with	O
B16	O
melanoma	O
.	O
A	O
substitution	O
of	O
DTrp	O
(	O
8	O
)	O
by	O
D2Nal	O
(	O
8	O
)	O
in	O
7	O
to	O
yield	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
D2Nal	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
13	O
)	O
and	O
in	O
16	O
to	O
yield	O
des	O
-	O
AA	O
(	O
1,5	O
)	O
-	O
[	O
Tyr	O
(	O
2	O
)	O
,	O
D2Nal	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
]	O
-	O
SRIF	O
(	O
17	O
)	O
was	O
intended	O
to	O
increase	O
chemical	O
stability	O
,	O
selectivity	O
,	O
and	O
affinity	O
and	O
resulted	O
in	O
two	O
analogues	O
that	O
were	O
less	O
potent	O
or	O
equipotent	O
with	O
similar	O
selectivity	O
,	O
respectively	O
.	O
The	O
family	O
of	O
cyclosteroids	O
should	O
be	O
useful	O
for	O
future	O
structure	O
-	O
activity	O
relationship	O
studies	O
of	O
steroid	O
modulation	O
of	O
other	O
GABA	O
(	O
A	O
)	O
receptor	O
subtypes	O
.	O
All	O
the	O
bromomethylpyrazole	O
nucleosides	O
described	O
showed	O
significant	O
cytostatic	O
activity	O
against	O
HeLa	O
cell	O
cultures	O
.	O
A	O
number	O
of	O
3	B-PARTIUPAC
-	I-PARTIUPAC
bromo	I-PARTIUPAC
-	I-PARTIUPAC
,	O
3	B-PARTIUPAC
-	I-PARTIUPAC
nitro	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
3	B-IUPAC
-	I-IUPAC
ethoxycarbonyl	I-IUPAC
-	I-IUPAC
5,7	I-IUPAC
-	I-IUPAC
dialkylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
were	O
synthesized	O
and	O
screened	O
as	O
in	O
vitro	O
cAMP	O
phosphodiesterase	O
inhibitors	O
.	O
The	O
presence	O
of	O
a	O
5	B-IUPAC
-	I-IUPAC
hydroxyl	I-IUPAC
group	B-MODIFIER
increased	O
selectivity	O
of	O
flavonols	O
for	O
human	O
A3	O
receptors	O
.	O
Two	O
of	O
the	O
designed	O
ligands	O
(	O
10e	O
and	O
10f	O
)	O
showed	O
the	O
highest	O
affinities	O
(	O
34	O
and	O
24	O
nM	O
,	O
respectively	O
)	O
reported	O
so	O
far	O
for	O
a	O
DAG	O
analogue	O
.	O
In	O
contrast	O
,	O
reaction	O
of	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
11a	O
)	O
with	O
sodium	O
carbonate	O
in	O
methanol	O
afforded	O
a	O
mixture	O
of	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxyethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
13	O
)	O
and	O
2,3	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
furano	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
(	I-IUPAC
5H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
14	O
)	O
.	O
The	O
N	B-IUPAC
-	I-IUPAC
allylindoline	I-IUPAC
4d	O
is	O
more	O
potent	O
than	O
idazoxan	O
in	O
vitro	O
and	O
is	O
equipotent	O
in	O
vivo	O
,	O
but	O
is	O
less	O
receptor	O
selective	O
(	O
alpha	O
2	O
vs.	O
alpha	O
1	O
)	O
than	O
idazoxan	O
.	O
Condensation	O
of	O
2	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
tert	I-PARTIUPAC
-	I-PARTIUPAC
butylsulfenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbomethoxyethyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
]	I-IUPAC
tryptophan	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
,	O
obtained	O
by	O
reaction	O
of	O
methyl	B-IUPAC
3a	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,3	I-IUPAC
a	I-IUPAC
,	I-IUPAC
8,8	I-IUPAC
a	I-IUPAC
-	I-IUPAC
hexahydropyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxyla	I-IUPAC
te	I-IUPAC
with	O
the	O
corresponding	O
thiol	O
,	O
with	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
OSu	O
afforded	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
t	O
-	O
BuS	O
)	O
-	O
OMe	O
and	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
CmES	O
)	O
-	O
OMe	O
,	O
which	O
on	O
treatment	O
with	O
Me3SiI	O
/	O
CH3CN	O
provided	O
23	O
and	O
24	O
,	O
respectively	O
.	O
1c	O
was	O
equally	O
potent	O
against	O
a	O
CHO	O
variant	O
that	O
was	O
20	O
-	O
fold	O
resistant	O
to	O
FU	O
.	O
Polyamines	O
containing	O
two	O
nitrogen	O
atoms	O
showed	O
optimal	O
binding	O
at	O
both	O
sigma	O
-	O
1	O
and	O
sigma	O
-	O
2	O
receptor	O
subtypes	O
.	O
6	B-IUPAC
-	I-IUPAC
Deoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
galactose	I-IUPAC
and	O
its	O
enantiomer	O
4a	O
were	O
found	O
to	O
be	O
effective	O
inhibitors	O
of	O
D	B-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
galactose	I-IUPAC
and	O
L	B-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
fucose	I-IUPAC
incorporation	O
,	O
respectively	O
,	O
into	O
macromolecular	O
components	O
of	O
human	O
mammary	O
tumor	O
cells	O
.	O
The	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
N6	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrobenzyladenine	I-IUPAC
and	O
its	O
ribonucleoside	O
were	O
found	O
to	O
be	O
noncompetitive	O
inhibitors	O
of	O
adenosine	O
aminohydrolase	O
.	O
As	O
with	O
DENSPM	O
and	O
(	O
2R	O
,	O
10R	O
)	O
-	O
(	O
HO	O
)	O
(	O
2	O
)	O
DENSPM	O
,	O
both	O
cyclopropyl	B-PARTIUPAC
analogues	B-MODIFIER
diminished	O
ornithine	O
decarboxylase	O
and	O
S	B-IUPAC
-	I-IUPAC
adenosylmethionine	I-IUPAC
decarboxylase	O
activity	O
.	O
The	O
incorporation	O
of	O
these	O
residues	O
in	O
the	O
mAZ	O
-	O
pTyr	O
-	O
Xaa	O
-	O
Asn	O
-	O
NH2	O
series	O
provided	O
compounds	O
with	O
very	O
high	O
affinity	O
for	O
the	O
Grb2	O
SH2	O
domain	O
,	O
in	O
the	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
9	O
)	O
range	O
of	O
Kd	O
values	O
.	O
Compound	O
3	O
inhibited	O
the	O
growth	O
of	O
tumor	O
cells	O
in	O
culture	O
(	O
IC50	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
while	O
4	O
showed	O
a	O
low	O
level	O
of	O
growth	O
inhibitory	O
activity	O
.	O
Specifically	O
-	O
CH2CH2	O
-	O
and	O
-	O
CH2NHCH2	O
-	O
bridged	O
analogues	O
,	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diaminofuro	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
3	O
)	O
and	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
diaminofuro	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
benzoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamic	I-IUPAC
acid	I-IUPAC
(	O
4	O
)	O
,	O
respectively	O
,	O
were	O
synthesized	O
.	O
Both	O
the	O
interaction	O
with	O
the	O
receptor	O
and	O
inhibition	O
of	O
cell	O
growth	O
by	O
these	O
two	O
glucocorticoids	O
are	O
reversible	O
.	O
Structural	O
alterations	O
in	O
both	O
series	O
did	O
little	O
to	O
enhance	O
the	O
inhibitory	O
activity	O
of	O
the	O
parent	O
compounds	O
2,6	B-IUPAC
-	I-IUPAC
dihydroxyacetophenone	I-IUPAC
(	O
3	O
)	O
and	O
2,4	B-IUPAC
-	I-IUPAC
dihydroxyacetophenone	I-IUPAC
(	O
27	O
)	O
.	O
These	O
monomethyl	O
ester	O
precursors	O
were	O
synthesized	O
from	O
the	O
known	O
analogous	O
aldehyde	O
via	O
an	O
O	B-IUPAC
-	I-IUPAC
trimethylsilyl	I-IUPAC
cyanohydrin	I-IUPAC
.	O
To	O
investigate	O
the	O
fate	O
of	O
radiolabels	O
after	O
lysosomal	O
proteolysis	O
,	O
hepatic	O
parenchymal	O
cells	O
were	O
used	O
as	O
a	O
model	O
nontarget	O
tissue	O
and	O
131I	O
-	O
labeled	O
MIH	O
was	O
conjugated	O
with	O
galactosyl	O
-	O
neoglycoalbumin	O
(	O
NGA	O
)	O
.	O
A	O
series	O
of	O
osteotropic	O
(	O
bone	O
-	O
seeking	O
)	O
[	B-IUPAC
(	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
phosphonomethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
kappaN	I-IUPAC
)	I-IUPAC
acetato	I-IUPAC
-	I-IUPAC
kappaO	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
)	I-IUPAC
]	I-IUPAC
platinum	I-IUPAC
(	I-IUPAC
II	I-IUPAC
)	I-IUPAC
complexes	B-MODIFIER
attached	O
to	O
diammine	B-IUPAC
,	O
ethane	B-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
,	O
cis	B-IUPAC
-	I-IUPAC
R	I-IUPAC
,	I-IUPAC
S	I-IUPAC
-	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
,	O
trans	B-IUPAC
-	I-IUPAC
S	I-IUPAC
,	I-IUPAC
S	I-IUPAC
-	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
,	O
or	O
trans	B-IUPAC
-	I-IUPAC
R	I-IUPAC
,	I-IUPAC
R	I-IUPAC
-	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
diamine	I-IUPAC
has	O
been	O
synthesized	O
in	O
accord	O
with	O
the	O
concept	O
of	O
drug	O
targeting	O
and	O
characterized	O
by	O
elemental	O
analysis	O
,	O
(	O
1	O
)	O
H	O
,	O
(	O
13	O
)	O
C	O
,	O
and	O
(	O
31	O
)	O
P	O
NMR	O
spectroscopy	O
.	O
In	O
the	O
second	O
approach	O
,	O
the	O
iodination	O
of	O
a	O
17	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
18,19,20	I-IUPAC
-	I-IUPAC
trinorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
derivative	B-MODIFIER
delivered	O
17	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
18,19,20	I-IUPAC
-	I-IUPAC
trinorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
,	O
which	O
exhibited	O
competitive	O
binding	O
with	O
natural	O
[	O
3H	O
]	O
PGF2	O
alpha	O
to	O
ovine	O
luteal	O
cells	O
and	O
to	O
plasma	O
membranes	O
of	O
bovine	O
corpora	O
lutea	O
.	O
These	O
compounds	O
and	O
the	O
corresponding	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	O
and	O
4	B-IUPAC
-	I-IUPAC
hydroxyimidazol	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,2,6	I-IUPAC
]	I-IUPAC
thiadiazine	I-IUPAC
2,2	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
were	O
examined	O
as	O
potential	O
transition	O
-	O
state	O
analogue	O
inhibitors	O
of	O
xanthine	O
oxidase	O
and	O
guanine	O
aminohydrolase	O
.	O
The	O
corresponding	O
unsaturated	O
analog	O
of	O
11	O
,	O
compound	O
14	O
,	O
showed	O
a	O
slightly	O
weaker	O
receptor	O
affinity	O
(	O
IC50	O
=	O
4.0	O
+	O
/	O
-	O
2.0	O
microM	O
)	O
but	O
a	O
significantly	O
higher	O
relative	O
efficacy	O
(	O
50-55%	O
)	O
than	O
11	O
.	O
Reductive	O
dialkylation	O
of	O
THF	O
with	O
formaldehyde	O
gave	O
5,10	O
-	O
(	O
CH3	O
)	O
2	O
-	O
THF	O
(	O
27	O
)	O
,	O
whereas	O
glyoxal	O
gave	O
5,10	O
-	O
CH2CH2	O
)	O
-	O
THF	O
(	O
10	O
)	O
.	O
These	O
substitutions	O
were	O
designed	O
to	O
probe	O
the	O
spatial	O
limitations	O
of	O
the	O
receptor	O
's	O
cavity	O
and	O
to	O
map	O
the	O
steric	O
and	O
ionic	O
boundaries	O
.	O
Finally	O
,	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chlorothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyluracil	I-IUPAC
and	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bromothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyluracil	I-IUPAC
were	O
obtained	O
by	O
halogenation	O
of	O
5	B-IUPAC
-	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyluracil	I-IUPAC
.	O
None	O
of	O
these	O
new	O
compounds	O
showed	O
detectable	O
effects	O
at	O
N	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
d	I-IUPAC
-	I-IUPAC
aspartic	I-IUPAC
acid	I-IUPAC
(	O
NMDA	O
)	O
or	O
kainic	O
acid	O
receptors	O
in	O
vitro	O
.	O
Both	O
were	O
found	O
to	O
be	O
substantially	O
longer	O
acting	O
after	O
oral	O
administration	O
than	O
the	O
corresponding	O
S	O
enantiomers	O
in	O
the	O
guinea	O
pig	O
bronchoconstriction	O
assay	O
.	O
1994	O
,	O
116	O
,	O
429-436	O
)	O
.	O
This	O
was	O
converted	O
to	O
(	B-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5,12	I-IUPAC
-	I-IUPAC
dimethoxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azanaphthacene	I-IUPAC
-	I-IUPAC
6,11	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
by	O
dehydration	O
to	O
the	O
4	B-IUPAC
-	I-IUPAC
keto	I-IUPAC
analogue	B-MODIFIER
followed	O
by	O
cyanoborohydride	O
reduction	O
either	O
stepwise	O
or	O
in	O
situ	O
.	O
Our	O
studies	O
identify	O
an	O
absolute	O
requirement	O
for	O
the	O
carboxylic	O
acid	O
moiety	O
on	O
the	O
aromatic	O
ring	O
to	O
be	O
para	O
relative	O
to	O
the	O
amide	O
linkage	O
for	O
activity	O
.	O
All	O
of	O
the	O
diamidines	O
showed	O
strong	O
DNA	O
affinities	O
as	O
judged	O
by	O
high	O
DeltaT	O
(	O
m	O
)	O
values	O
.	O
)	O
afforded	O
symmetrical	O
dialkylpyrazolo	B-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
(	O
5	O
)	O
.	O
Pyrazolo	O
[	O
3,4	O
-	O
d	O
]	O
pyrimidines	O
are	O
pyrazolo	O
analogues	O
of	O
purines	O
.	O
Its	O
inhibitory	O
activity	O
in	O
IL	O
-	O
4	O
production	O
test	O
from	O
Th	O
-	O
2	O
cells	O
was	O
identical	O
to	O
that	O
of	O
the	O
reference	O
histamine	O
antagonist	O
(	O
IC50	O
=	O
8.0	O
microM	O
)	O
and	O
twice	O
higher	O
in	O
IL	O
-	O
5	O
assay	O
:	O
IC50	O
=	O
1.5	O
and	O
3.3	O
microM	O
,	O
respectively	O
.	O
The	O
most	O
potent	O
compound	O
,	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
1benzothieno2	I-IUPAC
,	I-IUPAC
3	I-IUPAC
-	I-IUPAC
d1	I-IUPAC
,	I-IUPAC
3	I-IUPAC
\C5	I-IUPAC
\8F	I-IUPAC
xazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
exhibited	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
5.8	O
nM	O
.	O
Long	O
duration	O
of	O
action	O
was	O
demonstrated	O
both	O
in	O
ex	O
vivo	O
binding	O
(	O
T1/2	O
approximately	O
20	O
h	O
)	O
and	O
in	O
the	O
black	O
/	O
white	O
box	O
exploration	O
test	O
.	O
In	O
addition	O
,	O
3	O
was	O
equipotent	O
with	O
1	O
and	O
2	O
in	O
[	O
(	O
3	O
)	O
H	O
]	O
dopamine	O
uptake	O
inhibition	O
studies	O
,	O
while	O
4	O
was	O
10	O
-	O
fold	O
less	O
potent	O
.	O
The	O
benzopyran	O
and	O
naphthopyran	O
derivatives	O
were	O
prepared	O
by	O
the	O
classical	O
von	O
Pechmann	O
reaction	O
.	O
Of	O
those	O
,	O
some	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
acylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbamoylimidazoles	I-IUPAC
and	O
2	B-IUPAC
-	I-IUPAC
thioalkyl	I-IUPAC
-	O
substituted	B-MODIFIER
purines	B-IUPAC
exhibited	O
very	O
good	O
inhibitory	O
activity	O
,	O
being	O
at	O
least	O
500	O
times	O
more	O
effective	O
than	O
allopurinol	O
.	O
These	O
compounds	O
will	O
allow	O
further	O
study	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
"	O
cocaine	O
"	O
receptor	O
as	O
well	O
as	O
the	O
development	O
of	O
potential	O
cocaine	O
antagonists	O
.	O
Compounds	O
(	O
+	O
)	O
-	O
1	O
,	O
(	O
-	O
)	O
-	O
1	O
,	O
(	O
-	O
)	O
-	O
2	O
,	O
and	O
(	O
+	O
)	O
-	O
2	O
were	O
compared	O
for	O
their	O
binding	O
affinities	O
at	O
kappa	O
opioid	O
,	O
sigma	O
,	O
D2	B-IUPAC
-	I-IUPAC
dopamine	I-IUPAC
,	O
and	O
phencyclidine	O
(	O
PCP	O
)	O
receptors	O
in	O
competitive	O
binding	O
assays	O
using	O
[	O
3H	O
]	O
bremazocine	O
(	O
[	O
3H	O
]	O
BREM	O
)	O
or	O
[	O
3H	O
]	O
U69	O
,	O
593	O
,	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
[	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
3	O
-	O
PPP	O
]	O
,	O
or	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
di	I-IUPAC
(	I-IUPAC
o	I-IUPAC
-	I-IUPAC
tolyl	I-IUPAC
)	I-IUPAC
guanidine	I-IUPAC
(	O
[	O
3H	O
]	O
DTG	O
)	O
,	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
sulpiride	I-IUPAC
[	O
[	O
3H	O
]	O
-	O
(	O
-	O
)	O
SULP	O
]	O
,	O
and	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thienyl	I-IUPAC
)	I-IUPAC
cyclohexyl	I-IUPAC
]	I-IUPAC
piperidine	I-IUPAC
(	O
[	O
3H	O
]	O
TCP	O
)	O
,	O
respectively	O
.	O
The	O
synthesis	O
of	O
various	O
substituted	B-MODIFIER
5	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylic	I-IUPAC
acids	I-IUPAC
and	O
their	O
derivatives	O
is	O
described	O
by	O
three	O
general	O
methods	O
:	O
(	O
1	O
)	O
reductive	O
alkylation	O
of	O
methyl	B-IUPAC
5	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylates	I-IUPAC
(	O
2	O
)	O
and	O
subsequent	O
hydrolysis	O
;	O
(	O
2	O
)	O
alkylation	O
of	O
the	O
urethane	O
(	O
9	O
)	O
,	O
followed	O
by	O
hydrolysis	O
;	O
and	O
(	O
3	O
)	O
selective	O
NaBH4	O
reduction	O
of	O
the	O
appropriate	O
amide	O
of	O
(	O
2	O
)	O
,	O
followed	O
by	O
hydrolysis	O
.	O
Although	O
beta	B-IUPAC
,	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
methylene	I-IUPAC
-	I-IUPAC
ATP	I-IUPAC
was	O
inactive	O
at	O
P2Y	O
receptors	O
,	O
beta	B-IUPAC
,	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
methylene	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methanocarba	I-IUPAC
-	I-IUPAC
ATP	I-IUPAC
was	O
a	O
potent	O
hP2Y	O
(	O
1	O
)	O
receptor	O
agonist	O
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
160	O
nM	O
and	O
was	O
selective	O
versus	O
hP2Y	O
(	O
2	O
)	O
and	O
hP2Y	O
(	O
4	O
)	O
receptors	O
.	O
Unexpectedly	O
it	O
was	O
not	O
possible	O
to	O
remove	O
the	O
N	B-IUPAC
-	I-IUPAC
trifluoroacetyl	I-IUPAC
blocking	B-MODIFIER
group	I-MODIFIER
without	O
aromatization	O
to	O
the	O
azanaphthaquinone	O
.	O
Other	O
potent	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
compounds	B-MODIFIER
are	O
those	O
in	O
which	O
the	O
heterocyclic	O
imine	O
is	O
replaced	O
with	O
pyrrolidine	O
(	O
19	O
)	O
(	O
IC50	O
9	O
nM	O
)	O
or	O
trimethylammonium	O
(	O
22	O
)	O
(	O
IC50	O
18	O
nM	O
)	O
.	O
The	O
binding	O
affinity	O
of	O
the	O
multimeric	O
RGD	O
compounds	O
for	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
receptor	O
(	O
ABIR	O
)	O
showed	O
a	O
remarkable	O
increase	O
relative	O
to	O
the	O
monomer	O
cypate	O
-	O
RGD	O
-	O
NH	O
(	O
2	O
)	O
.	O
The	O
T	O
/	O
C	O
values	O
of	O
281	O
and	O
300	O
were	O
obtained	O
for	O
compounds	O
11	O
and	O
12	O
,	O
respectively	O
,	O
in	O
the	O
case	O
of	O
mice	O
bearing	O
EAC	O
cells	O
.	O
Furthermore	O
,	O
(	B-IUPAC
3RS	I-IUPAC
,	I-IUPAC
4SR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypiperidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
14	O
)	O
,	O
related	O
to	O
the	O
specific	O
GABA	O
agonist	O
piperidine	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
isonipecotic	O
acid	O
)	O
,	O
has	O
been	O
synthesized	O
.	O
Base	O
-	O
catalyzed	O
elimination	O
of	O
HBr	O
resulted	O
in	O
the	O
formation	O
of	O
(	B-PARTIUPAC
Z	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	B-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylenecyclopropanecarboxylic	I-IUPAC
esters	I-IUPAC
26	O
+	O
27	O
.	O
Deprotection	O
of	O
the	O
key	O
intermediate	O
1,4	B-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
allyl	I-IUPAC
-	I-IUPAC
2,5,6	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
by	O
isomerization	O
of	O
allyl	O
groups	O
followed	O
by	O
mild	O
acid	O
hydrolysis	O
gave	O
2,4,5	B-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
,	O
which	O
was	O
converted	O
to	O
the	O
diastereoisomeric	O
(	O
bis	B-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
camphanates	I-IUPAC
.	O
The	O
IC	O
(	O
50	O
)	O
values	O
ranged	O
from	O
0.5	O
to	O
26	O
nM	O
.	O
However	O
,	O
their	O
usefulness	O
for	O
in	O
vivo	O
chelation	O
of	O
actinide	O
(	O
IV	O
)	O
is	O
limited	O
,	O
because	O
catechol	O
and	O
hydroxamate	O
are	O
such	O
weak	O
acids	O
that	O
the	O
potential	O
for	O
octadentate	O
binding	O
of	O
actinide	O
(	O
IV	O
)	O
cannot	O
be	O
achieved	O
at	O
physiological	O
pH	O
.	O
In	O
the	O
colon	O
cancer	O
cell	O
studies	O
,	O
trans	O
-	O
[	O
PtCl2	O
(	O
NH3	O
)	O
(	O
pip	O
-	O
pip	O
)	O
]	O
x	O
HCl	O
was	O
slightly	O
less	O
potent	O
than	O
cisplatin	O
in	O
the	O
in	O
vitro	O
studies	O
but	O
had	O
efficacy	O
comparable	O
to	O
that	O
of	O
cisplatin	O
in	O
the	O
in	O
vivo	O
xenograft	O
model	O
.	O
These	O
compounds	O
may	O
be	O
useful	O
as	O
delivery	O
agents	O
for	O
boron	O
neutron	O
capture	O
therapy	O
.	O
Activity	O
at	O
P2X	O
-	O
purinoceptors	O
was	O
established	O
by	O
measurement	O
of	O
contraction	O
of	O
rabbit	O
saphenous	O
artery	O
and	O
of	O
the	O
guinea	O
pig	O
vas	O
deferens	O
and	O
urinary	O
bladder	O
.	O
Structure	O
-	O
activity	O
studies	O
revealed	O
that	O
substitution	O
and	O
geometry	O
of	O
this	O
alkyl	O
group	O
,	O
and	O
substitution	O
on	O
the	O
benzodioxolyl	O
ring	O
,	O
are	O
important	O
in	O
optimizing	O
this	O
series	O
of	O
highly	O
ETA	O
selective	O
antagonists	O
.	O
,	O
2	B-IUPAC
-	I-IUPAC
acetylpyridine	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylthiosemicarbazone	I-IUPAC
(	O
1	O
)	O
,	O
2	B-IUPAC
-	I-IUPAC
acetylpyridine	I-IUPAC
N	I-IUPAC
-	I-IUPAC
pyrrolidinylthiosemicarbazone	I-IUPAC
(	O
2	O
)	O
,	O
acetylpyrazine	B-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylthiosemicarbazone	I-IUPAC
(	O
3	O
)	O
,	O
acetylpyrazine	B-IUPAC
N	I-IUPAC
-	I-IUPAC
pyrrolidinylthiosemicarbazone	I-IUPAC
(	O
4	O
)	O
,	O
and	O
acetylpyrazine	B-IUPAC
N	I-IUPAC
-	I-IUPAC
piperidinylthiosemicarbazone	I-IUPAC
(	O
5	O
)	O
,	O
with	O
the	O
general	O
formula	O
[	O
GaLCl2	O
]	O
(	O
HL	O
=	O
1	O
and	O
2	O
)	O
and	O
[	O
ML2	O
]	O
[	O
Y	O
]	O
(	O
M	O
=	O
Ga	O
,	O
HL	O
=	O
1-5	O
,	O
Y	O
=	O
PF6	O
;	O
M	O
=	O
Fe	O
,	O
HL	O
=	O
1-5	O
,	O
Y	O
=	O
FeCl4	O
and	O
PF6	O
)	O
were	O
synthesized	O
and	O
characterized	O
by	O
elemental	O
analysis	O
,	O
a	O
number	O
of	O
spectroscopic	O
methods	O
(	O
NMR	O
,	O
IR	O
,	O
UV	O
-	O
vis	O
)	O
,	O
mass	O
spectrometry	O
,	O
and	O
X	O
-	O
ray	O
crystallography	O
.	O
Molecular	O
modeling	O
and	O
docking	O
to	O
a	O
crystal	O
structure	O
of	O
the	O
extracellular	O
binding	O
domain	O
of	O
the	O
AMPA	O
subunit	O
GluR2	O
has	O
enabled	O
identification	O
of	O
the	O
probable	O
active	O
conformation	O
and	O
binding	O
mode	O
of	O
6	O
.	O
The	O
pharmacological	O
results	O
indicate	O
that	O
this	O
isosteric	O
replacement	O
results	O
in	O
higher	O
selectivity	O
for	O
5	O
-	O
HT2	O
receptors	O
compared	O
to	O
the	O
former	O
series	O
.	O
Condensation	O
of	O
optically	O
pure	O
(	O
-	O
)	O
-	O
10	O
and	O
(	O
+	O
)	O
-	O
10	O
with	O
3,4	B-IUPAC
-	I-IUPAC
dichlorophenylacetic	I-IUPAC
acid	I-IUPAC
furnished	O
(	O
+	O
)	O
-	O
1	O
and	O
(	O
-	O
)	O
-	O
1	O
,	O
respectively	O
.	O
However	O
,	O
when	O
silylated	O
DTPC	O
was	O
reacted	O
with	O
2	B-IUPAC
-	I-IUPAC
chlorotetrahydropyran	I-IUPAC
,	O
two	O
tetrahydropyran	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
compounds	B-MODIFIER
were	O
obtained	O
,	O
and	O
these	O
were	O
shown	O
to	O
be	O
positional	O
isomers	O
on	O
the	O
basis	O
of	O
1H	O
NMR	O
and	O
UV	O
data	O
.	O
Diphenylphosphoryl	O
azide	O
was	O
used	O
as	O
the	O
coupling	O
reagent	O
in	O
each	O
conversion	O
producing	O
a	O
peptide	O
linkage	O
.	O
Oxidative	O
cyclization	O
of	O
either	O
4,5	B-PARTIUPAC
-	I-PARTIUPAC
or	O
5,6	B-IUPAC
-	I-IUPAC
diaminopyridines	I-IUPAC
with	O
aryl	O
aldehydes	O
produced	O
the	O
[	O
4,5	O
-	O
c	O
]	O
and	O
[	O
4,5	O
-	O
b	O
]	O
imidazopyridine	O
ring	O
systems	O
,	O
respectively	O
.	O
Jones	O
'	O
oxidation	O
of	O
17	B-PARTIUPAC
beta	I-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
compounds	B-MODIFIER
gave	O
the	O
17	B-IUPAC
-	I-IUPAC
keto	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azasteroids	I-IUPAC
,	O
which	O
were	O
treated	O
with	O
amines	O
and	O
NaBH	O
(	O
OAc	O
)	O
3	O
/	O
NaBH3CN	O
to	O
give	O
17	B-IUPAC
beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
/	I-IUPAC
arylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
azasteroids	I-IUPAC
10-27	O
.	O
)	O
gave	O
a	O
mixture	O
of	O
5	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
alkylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
3	O
)	O
and	O
5	B-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
methylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
(	O
4	O
)	O
.	O
08	O
mg	O
/	O
kg	O
)	O
.	O
In	O
vivo	O
antitumor	O
evaluation	O
in	O
mice	O
against	O
L1210	O
lymphoid	O
leukemia	O
indicated	O
no	O
significant	O
activity	O
for	O
compound	O
2	O
.	O
However	O
,	O
the	O
heterocycles	O
and	O
several	O
of	O
the	O
N	O
-	O
4	O
glycosylated	O
derivatives	O
were	O
toxic	O
to	O
HFF	O
,	O
KB	O
and	O
L1210	O
cells	O
;	O
compounds	O
with	O
5	B-IUPAC
-	I-IUPAC
benzylthio	I-IUPAC
substituents	B-MODIFIER
were	O
the	O
most	O
cytotoxic	O
agents	O
in	O
this	O
series	O
.	O
tthe	O
most	O
potent	O
inhibitor	O
was	O
5	B-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dihydroxyacetophenone	I-IUPAC
(	O
31	O
)	O
.	O
The	O
results	O
of	O
the	O
study	O
indicated	O
that	O
the	O
conformations	O
of	O
PCP	O
represented	O
by	O
6-9	O
are	O
not	O
optimal	O
for	O
potent	O
interaction	O
at	O
either	O
of	O
these	O
sites	O
.	O
Structure	O
-	O
activity	O
relationships	O
have	O
been	O
investigated	O
for	O
inhibition	O
of	O
DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
and	O
ATM	O
kinase	O
by	O
a	O
series	O
of	O
pyran	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
pyran	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
thiopyran	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
and	O
pyridin	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O
malayiat	O
50	O
mg	O
/	O
kg	O
x	O
5	O
days	O
(	O
ip	O
)	O
or	O
at	O
200	O
mg	O
/	O
kg	O
x	O
5	O
days	O
(	O
po	O
)	O
.	O
[	O
dPen1	O
,	O
cyclo	O
(	O
Glu4	O
,	O
Lys8	O
)	O
]	O
oxytocin	O
also	O
was	O
a	O
weak	O
antagonist	O
in	O
the	O
pressor	O
assay	O
with	O
a	O
pA2	O
of	O
6.3	O
.	O
A	O
series	O
of	O
analogues	O
of	O
the	O
analgesic	O
dipeptide	O
derivative	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
has	O
been	O
designed	O
to	O
determine	O
the	O
influence	O
of	O
the	O
(	B-IUPAC
2	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
sulfenyl	I-IUPAC
(	O
NPS	O
)	O
moiety	B-MODIFIER
on	O
the	O
activity	O
.	O
Using	O
the	O
active	O
analog	O
approach	O
,	O
a	O
model	O
is	O
developed	O
of	O
a	O
region	O
of	O
steric	O
interference	O
at	O
this	O
receptor	O
using	O
the	O
active	O
cannabinoids	O
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
9	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
,	O
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
,	O
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
hexahydrocannabinol	I-IUPAC
,	O
and	O
a	O
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
dimethylheptyl	I-IUPAC
derivative	B-MODIFIER
and	O
the	O
inactive	O
cannabinoids	O
(	B-IUPAC
9S	I-IUPAC
,	I-IUPAC
6aR	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
10,10	I-IUPAC
a	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
and	O
a	O
(	B-IUPAC
+	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
delta	I-IUPAC
8	I-IUPAC
-	I-IUPAC
tetrahydrocannabinol	I-IUPAC
dimethylheptyl	I-IUPAC
derivative	B-MODIFIER
.	O
They	O
have	O
also	O
demonstrated	O
potential	O
clinical	O
efficacy	O
in	O
combating	O
HIV	O
-	O
1	O
,	O
on	O
the	O
basis	O
of	O
a	O
preliminary	O
study	O
.	O
Compounds	O
3-7	O
were	O
also	O
more	O
active	O
than	O
the	O
parent	O
drug	O
(	O
1	O
)	O
on	O
oral	O
administration	O
.	O
The	O
superimposition	O
of	O
contour	O
maps	O
on	O
the	O
active	O
site	O
of	O
serine	O
proteases	O
additionally	O
helps	O
in	O
understanding	O
the	O
structural	O
requirements	O
of	O
these	O
inhibitors	O
.	O
The	O
analogues	O
FDESPM	O
,	O
PIP	O
(	O
4,4,4	O
)	O
,	O
and	O
PYR	O
(	O
4,4,4	O
)	O
have	O
distances	O
between	O
their	O
nitrogen	O
atoms	O
almost	O
identical	O
to	O
those	O
of	O
DESPM	O
.	O
Upon	O
incubation	O
at	O
pH	O
7.4	O
and	O
37	O
degrees	O
C	O
,	O
it	O
undergoes	O
a	O
slow	O
hydrolysis	O
with	O
linear	O
regeneration	O
of	O
insulin	O
possessing	O
full	O
biological	O
potency	O
.	O
On	O
the	O
basis	O
of	O
in	O
vivo	O
functional	O
tests	O
,	O
8	B-IUPAC
-	I-IUPAC
phenylpiperazinoethylamino	I-IUPAC
(	O
11	O
)	O
,	O
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
methoxyphenylpiperazino	I-IUPAC
)	I-IUPAC
ethylamino	I-IUPAC
(	O
13	O
)	O
,	O
and	O
8	B-IUPAC
-	I-IUPAC
phenylpiperazinopropylamino	I-IUPAC
(	O
14	O
)	O
derivatives	B-MODIFIER
of	O
1,3	B-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
,	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
pyrimido	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
f	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
were	O
identified	O
as	O
potent	O
pre	O
-	O
and	O
postsynaptic	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptor	O
antagonists	O
.	O
Rotationally	O
restricted	O
analogues	O
of	O
5	B-IUPAC
-	I-IUPAC
deazapteroyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
and	O
(	B-IUPAC
6R	I-IUPAC
,	I-IUPAC
6S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
deaza	I-IUPAC
-	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydropteroyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutamate	I-IUPAC
with	O
a	O
one	O
-	O
carbon	O
bridge	O
between	O
the	O
amide	O
nitrogen	O
and	O
the	O
6'	O
-	O
position	O
of	O
the	O
p	B-IUPAC
-	I-IUPAC
aminobenzoyl	I-IUPAC
moiety	B-MODIFIER
were	O
synthesized	O
and	O
tested	O
as	O
substrates	O
for	O
folylpolyglutamate	O
synthetase	O
(	O
FPGS	O
)	O
,	O
a	O
key	O
enzyme	O
in	O
folate	O
metabolism	O
and	O
an	O
important	O
determinant	O
of	O
the	O
therapeutic	O
potency	O
and	O
selectivity	O
of	O
classical	O
antifolates	O
.	O
The	O
3	O
-	O
nitro	O
analogue	O
(	O
4	O
,	O
IC50	O
=	O
1.32	O
microM	O
)	O
has	O
a	O
pKa	O
approximately	O
5	O
and	O
thus	O
exists	O
at	O
physiological	O
pH	O
as	O
an	O
anion	O
with	O
the	O
nitro	O
group	O
planar	O
to	O
the	O
quinolone	O
ring	O
.	O
An	O
alkoxy	O
group	O
at	O
position	O
7	O
of	O
the	O
4	B-IUPAC
-	I-IUPAC
chromanone	I-IUPAC
moiety	B-MODIFIER
was	O
important	O
for	O
potent	O
ACAT	O
inhibitory	O
activity	O
.	O
Two	O
compounds	O
,	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxyanilino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
9	O
)	O
and	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxybenzyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
15	O
)	O
,	O
were	O
also	O
tested	O
against	O
human	O
DHFR	O
and	O
were	O
found	O
to	O
have	O
an	O
IC50	O
/	O
[	O
E	O
]	O
of	O
0.5	O
,	O
indicating	O
that	O
their	O
binding	O
was	O
near	O
-	O
stoichiometric	O
.	O
four	O
compounds	O
6a	O
,	O
6c	O
,	O
6d	O
,	O
and	O
8a	O
were	O
curative	O
.	O
The	O
compounds	O
(	B-IUPAC
1S	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylcyclopropyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dichlorophenyl	I-IUPAC
)	I-IUPAC
piperazine	I-IUPAC
(	O
5m	O
)	O
and	O
(	B-IUPAC
1S	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
trans	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylcyclopropyl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dimethylphenyl	I-IUPAC
)	I-IUPAC
piperazine	I-IUPAC
(	O
5t	O
)	O
were	O
selected	O
for	O
functional	O
antagonists	O
at	O
D	O
(	O
2	O
)	O
and	O
D	O
(	O
4	O
)	O
receptors	O
and	O
had	O
a	O
D	O
(	O
2	O
)	O
/	O
D	O
(	O
4	O
)	O
ratio	O
approximating	O
that	O
of	O
clozapine	O
;	O
they	O
proved	O
inactive	O
in	O
behavioral	O
tests	O
of	O
antipsychotic	O
activity	O
.	O
BTCP	O
and	O
7	O
were	O
the	O
most	O
potent	O
of	O
all	O
the	O
compounds	O
tested	O
in	O
terms	O
of	O
their	O
ability	O
to	O
inhibit	O
uptake	O
of	O
[	O
3H	O
]	O
DA	O
.	O
The	O
structurally	O
similar	O
monoprotic	O
and	O
more	O
acidic	O
1	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
pyridinone	I-IUPAC
(	O
1,2	O
-	O
HOPO	O
)	O
group	O
was	O
,	O
therefore	O
,	O
incorporated	O
into	O
multidentate	O
ligands	O
.	O
Treatment	O
of	O
the	O
iodohydrins	O
11a	O
-	O
c	O
with	O
methanolic	O
sulfuric	O
acid	O
afforded	O
the	O
corresponding	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
derivatives	B-MODIFIER
(	O
12a	O
-	O
c	O
)	O
.	O
This	O
provides	O
further	O
support	O
for	O
the	O
dopamine	O
hypothesis	O
of	O
cocaine	O
abuse	O
.	O
Water	O
-	O
soluble	O
prodrugs	O
of	O
potent	O
,	O
A	O
(	O
2A	O
)	O
-	O
selective	O
adenosine	O
receptor	O
(	O
AR	O
)	O
antagonists	O
were	O
prepared	O
.	O
The	O
higher	O
toxicity	O
of	O
neonicotinoid	O
insecticides	O
such	O
as	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropyridin	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
nitroiminoimidazolidine	I-IUPAC
(	O
imidacloprid	O
)	O
to	O
insects	O
than	O
mammals	O
is	O
due	O
in	O
large	O
part	O
to	O
target	O
site	O
specificity	O
at	O
the	O
corresponding	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChRs	O
)	O
.	O
A	O
number	O
of	O
N9	O
-	O
alkyl	O
-	O
substituted	O
purines	O
and	O
purine	O
ribonucleosides	O
have	O
been	O
synthesized	O
as	O
congeners	O
of	O
sulfinosine	O
and	O
evaluated	O
for	O
their	O
antileukemic	O
activity	O
in	O
mice	O
.	O
In	O
the	O
first	O
part	O
of	O
the	O
paper	O
,	O
we	O
report	O
the	O
synthesis	O
of	O
mimetics	O
of	O
the	O
constrained	O
(	O
alpha	O
-	O
Me	O
)	O
phosphotyrosine	O
residue	O
such	O
as	O
(	B-MODIFIER
alpha	I-MODIFIER
-	I-MODIFIER
Me	I-MODIFIER
)	I-MODIFIER
-	O
4	B-IUPAC
-	I-IUPAC
phosphonomethylphenylalanine	I-IUPAC
(	O
-	O
CH2PO3H2	O
)	O
,	O
(	B-MODIFIER
alpha	I-MODIFIER
-	I-MODIFIER
Me	I-MODIFIER
)	I-MODIFIER
4	B-IUPAC
-	I-IUPAC
phosphonodifluoromethylphenylalanine	I-IUPAC
(	O
-	O
CF2PO3H2	O
)	O
,	O
and	O
(	B-MODIFIER
alpha	I-MODIFIER
-	I-MODIFIER
Me	I-MODIFIER
)	I-MODIFIER
-	O
4	B-IUPAC
-	I-IUPAC
phosphonophenylalanine	I-IUPAC
(	O
-	O
PO3H2	O
)	O
.	O
Exchanging	O
the	O
isobenzofuran	O
moiety	O
of	O
Lu	O
28-179	O
with	O
thioisobenzofuran	O
,	O
benzofuran	O
,	O
or	O
benzopyran	O
also	O
has	O
a	O
pronounced	O
effect	O
on	O
both	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
binding	O
sites	O
.	O
Attempts	O
to	O
convert	O
20	O
or	O
23	O
to	O
bromocyclopropanes	O
21	O
and	O
22	O
by	O
reaction	O
with	O
ethyl	O
diazoacetate	O
catalyzed	O
by	O
Rh2	O
(	O
OAc	O
)	O
4	O
were	O
futile	O
.	O
The	O
3	O
-	O
bromo	O
derivatives	O
were	O
much	O
more	O
active	O
than	O
the	O
3	O
-	O
unsubstituted	O
analogs	O
in	O
both	O
the	O
cytotoxicity	O
,	O
and	O
antiviral	O
assays	O
.	O
The	O
synthesis	O
of	O
this	O
latter	O
compound	O
has	O
been	O
improved	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
,	O
for	O
comparative	O
purposes	O
,	O
halo	B-IUPAC
enol	I-IUPAC
lactones	I-IUPAC
with	O
aryl	O
functions	O
situated	O
beta	O
and	O
gamma	O
to	O
the	O
lactone	O
carbonyl	O
group	O
.	O
The	O
synthesis	O
and	O
pharmacological	O
activities	O
of	O
the	O
four	O
stereoisomers	O
of	O
methyl	B-IUPAC
tetrahydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
2,6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
-	I-IUPAC
3,5	I-IUPAC
-	I-IUPAC
dicarboxylate	I-IUPAC
(	I-IUPAC
furnidipine	I-IUPAC
)	I-IUPAC
are	O
reported	O
.	O
On	O
the	O
basis	O
of	O
these	O
results	O
,	O
a	O
model	O
accounting	O
for	O
glycine	O
receptor	O
binding	O
of	O
the	O
1	O
derived	O
antagonists	O
is	O
proposed	O
,	O
comprising	O
(	O
a	O
)	O
size	O
-	O
limited	O
,	O
hydrophobic	O
binding	O
of	O
the	O
benzene	O
ring	O
,	O
(	O
b	O
)	O
hydrogen	O
-	O
bond	O
acceptance	O
by	O
the	O
4	B-IUPAC
-	I-IUPAC
oxo	I-IUPAC
group	B-MODIFIER
,	O
(	O
c	O
)	O
hydrogen	O
-	O
bond	O
donation	O
by	O
the	O
1	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	B-MODIFIER
,	O
and	O
(	O
d	O
)	O
a	O
Coulombic	O
attraction	O
of	O
the	O
2	B-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
.	O
The	O
9	B-IUPAC
-	I-IUPAC
chlorodibenzodioxin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
was	O
also	O
curative	O
against	O
the	O
remotely	O
sited	O
Lewis	O
lung	O
carcinoma	O
.	O
Using	O
cultured	O
cerebral	O
cortical	O
neurons	O
and	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
techniques	O
,	O
the	O
efficacies	O
of	O
these	O
compounds	O
relative	O
to	O
that	O
of	O
the	O
full	O
GABAA	O
agonist	O
,	O
isoguvacine	O
(	O
8	O
)	O
(	O
20	O
microM	O
)	O
,	O
were	O
determined	O
.	O
Syntheses	O
of	O
several	O
carbamate	O
analogues	O
of	O
2	B-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amidinophenyl	I-IUPAC
)	I-IUPAC
furan	I-IUPAC
(	O
1	O
)	O
under	O
mild	O
conditions	O
and	O
their	O
evaluation	O
as	O
prodrugs	O
against	O
Pneumocystis	O
carinii	O
pneumonia	O
(	O
PCP	O
)	O
in	O
an	O
immunosuppressed	O
rat	O
model	O
are	O
described	O
.	O
Biochim	O
.	O
Binding	O
sites	O
with	O
the	O
lowest	O
affinity	O
for	O
II	O
were	O
found	O
in	O
cortical	O
,	O
striatal	O
,	O
and	O
hippocampal	O
regions	O
(	O
IC50	O
values	O
greater	O
than	O
2.0	O
microM	O
)	O
.	O
In	O
in	O
vitro	O
studies	O
,	O
IC50	O
(	O
microM	O
)	O
values	O
obtained	O
for	O
4	O
vs	O
L1210	O
and	O
S180	O
of	O
1.50	O
and	O
2.35	O
,	O
respectively	O
,	O
were	O
similar	O
to	O
those	O
obtained	O
for	O
PDDF	O
(	O
2.61	O
and	O
1.97	O
)	O
.	O
All	O
compounds	O
were	O
subjected	O
to	O
in	O
vitro	O
pharmacological	O
studies	O
,	O
including	O
a	O
series	O
of	O
Glu	O
receptor	O
binding	O
assays	O
,	O
uptake	O
studies	O
on	O
native	O
as	O
well	O
as	O
cloned	O
Glu	O
uptake	O
systems	O
,	O
and	O
the	O
electrophysiological	O
rat	O
cortical	O
slice	O
model	O
.	O
An	O
array	O
of	O
NIR	O
fluorescent	O
RGD	O
compounds	O
was	O
prepared	O
efficiently	O
,	O
including	O
one	O
RGD	O
monomer	O
(	O
cypate	O
-	O
(	O
RGD	O
)	O
(	O
2	O
)	O
-	O
NH	O
(	O
2	O
)	O
)	O
,	O
two	O
RGD	O
dimers	O
(	O
cypate	O
-	O
(	O
RGD	O
)	O
(	O
2	O
)	O
-	O
NH	O
(	O
2	O
)	O
and	O
cypate	O
-	O
(	O
RGD	O
-	O
NH	O
(	O
2	O
)	O
)	O
(	O
2	O
)	O
)	O
,	O
one	O
trimer	O
(	O
cypate	O
-	O
(	O
RGD	O
)	O
(	O
3	O
)	O
-	O
NH	O
(	O
2	O
)	O
)	O
,	O
two	O
tetramers	O
(	O
cypate	O
-	O
(	O
RGD	O
)	O
(	O
4	O
)	O
-	O
NH	O
(	O
2	O
)	O
and	O
cypate	O
-	O
[	O
(	O
RGD	O
)	O
(	O
2	O
)	O
-	O
NH	O
(	O
2	O
)	O
]	O
(	O
2	O
)	O
)	O
,	O
one	O
hexamer	O
(	O
cypate	O
-	O
[	O
(	O
RGD	O
)	O
(	O
3	O
)	O
-	O
NH	O
(	O
2	O
)	O
]	O
(	O
2	O
)	O
)	O
,	O
and	O
one	O
octamer	O
(	O
cypate	O
-	O
[	O
(	O
RGD	O
)	O
(	O
4	O
)	O
-	O
NH	O
(	O
2	O
)	O
]	O
(	O
2	O
)	O
)	O
.	O
In	O
order	O
to	O
determine	O
the	O
active	O
site	O
binding	O
orientation	O
of	O
norepinephrine	O
,	O
a	O
series	O
of	O
conformationally	O
defined	O
analogues	O
of	O
the	O
tyramines	O
,	O
in	O
which	O
the	O
ethylamine	O
side	O
chain	O
is	O
held	O
fixed	O
by	O
incorporation	O
into	O
a	O
benzonorbornene	O
skeleton	O
,	O
were	O
prepared	O
and	O
evaluated	O
for	O
phenylethanolamine	O
N	O
-	O
methyltransferase	O
(	O
PNMT	O
)	O
activity	O
.	O
The	O
most	O
active	O
quinazolines	O
against	O
both	O
the	O
P	O
.	O
Electrical	O
recordings	O
using	O
cloned	O
receptors	O
expressed	O
in	O
Xenopus	O
oocytes	O
show	O
that	O
high	O
-	O
potency	O
antagonists	O
at	O
the	O
NR1A	O
/	O
2B	O
subtype	O
are	O
obtained	O
employing	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
omega	I-IUPAC
-	I-IUPAC
phenylalkyl	I-IUPAC
)	I-IUPAC
-	O
substituted	B-MODIFIER
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
,	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxybenzyl	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
,	O
and	O
(	B-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
pyrrolidine	I-IUPAC
as	O
exemplified	O
by	O
21	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.022	O
microM	O
)	O
,	O
33	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.059	O
microM	O
)	O
,	O
and	O
40	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.017	O
microM	O
)	O
,	O
respectively	O
.	O
For	O
example	O
,	O
the	O
difference	O
between	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorobenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
dimethylethylenediamine	I-IUPAC
(	O
8	O
)	O
[	O
K	O
(	O
i	O
)	O
=	O
29.9	O
nM	O
at	O
sigma	O
-	O
1	O
receptor	O
and	O
18.3	O
nM	O
at	O
sigma	O
-	O
2	O
receptor	O
]	O
to	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
pyrrolidinyl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorobenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
dimethylethylenediamine	I-IUPAC
(	O
10	O
)	O
[	O
K	O
(	O
i	O
)	O
=	O
1.49	O
nM	O
at	O
sigma	O
-	O
1	O
receptor	O
and	O
12.1	O
nM	O
at	O
sigma	O
-	O
2	O
receptor	O
]	O
illustrates	O
the	O
importance	O
of	O
internitrogen	O
spacing	O
.	O
Seven	O
1,2	B-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydroacronycine	I-IUPAC
and	O
1,2	B-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
demethoxyacronycine	I-IUPAC
esters	I-IUPAC
and	O
diesters	O
were	O
synthesized	O
via	O
osmic	O
oxidation	O
of	O
acronycine	O
or	O
6	B-IUPAC
-	I-IUPAC
demethoxyacronycine	I-IUPAC
followed	O
by	O
acylation	O
.	O
For	O
a	O
better	O
understanding	O
of	O
structure	O
-	O
activity	O
relationships	O
,	O
the	O
interaction	O
of	O
1	O
and	O
10	O
,	O
13	O
and	O
14	O
within	O
the	O
transmembrane	O
(	O
TM	O
)	O
domains	O
of	O
the	O
human	O
histamine	O
H	O
(	O
1	O
)	O
receptor	O
were	O
studied	O
using	O
molecular	O
dynamics	O
simulations	O
.	O
The	O
novel	O
compounds	O
were	O
characterized	O
as	O
dopaminergic	O
antagonists	O
or	O
inverse	O
agonists	O
.	O
The	O
synthesis	O
of	O
all	O
but	O
one	O
class	O
was	O
achieved	O
by	O
acylation	O
and	O
alane	O
reduction	O
of	O
the	O
appropriate	O
diamine	O
precursors	O
whose	O
synthesis	O
is	O
also	O
reported	O
.	O
Ethanethiol	O
gave	O
3'	B-IUPAC
.5	I-IUPAC
'	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
hydroxyacetanilide	I-IUPAC
.	O
However	O
all	O
the	O
compounds	O
were	O
more	O
potent	O
against	O
the	O
rat	O
liver	O
enzyme	O
than	O
the	O
P	O
.	O
Closely	O
following	O
in	O
activity	O
in	O
decreasing	O
order	O
were	O
N3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylcarbamoyl	I-IUPAC
)	I-IUPAC
uracil	I-IUPAC
(	O
7	O
)	O
,	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylcarbamoyl	I-IUPAC
)	I-IUPAC
saccharin	I-IUPAC
(	O
6	O
)	O
,	O
and	O
the	O
S	B-IUPAC
-	I-IUPAC
(	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylcarbamoyl	I-IUPAC
)	I-IUPAC
derivative	B-MODIFIER
(	O
9	O
)	O
of	O
benzyl	B-IUPAC
mercaptan	I-IUPAC
.	O
The	O
hydroosmotic	O
activity	O
of	O
the	O
biotinyl	O
analogue	O
was	O
reversed	O
following	O
addition	O
of	O
avidin	O
,	O
whereas	O
the	O
photoaffinity	O
analogue	O
induced	O
a	O
persistent	O
response	O
following	O
UV	O
irradiation	O
that	O
was	O
not	O
reversed	O
upon	O
repeated	O
and	O
prolonged	O
periods	O
of	O
washout	O
.	O
However	O
,	O
members	O
of	O
the	O
thiadiazolopyrimidine	B-IUPAC
class	O
of	O
mesoionics	O
exhibited	O
very	O
low	O
or	O
no	O
activity	O
as	O
antagonists	O
of	O
A2	O
-	O
adenosine	O
receptors	O
while	O
exhibiting	O
activity	O
only	O
2-4	O
-	O
fold	O
lower	O
than	O
that	O
of	O
theophylline	O
at	O
A1	O
-	O
adenosine	O
receptors	O
.	O
Many	O
of	O
these	O
antagonists	O
,	O
for	O
example	O
ifenprodil	O
(	O
1	O
)	O
,	O
incorporate	O
a	O
4	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
substituent	B-MODIFIER
on	O
the	O
omega	O
-	O
phenyl	O
group	O
.	O
The	O
in	O
vitro	O
binding	O
results	O
from	O
symmetrically	O
substituted	O
diphenylguanidines	O
indicated	O
that	O
compounds	O
having	O
ortho	O
or	O
meta	O
substituents	O
(	O
with	O
respect	O
to	O
the	O
position	O
of	O
the	O
guanidine	O
nitrogen	O
)	O
on	O
the	O
phenyl	O
rings	O
showed	O
greater	O
affinity	O
for	O
the	O
NMDA	O
receptor	O
ion	O
channel	O
site	O
compared	O
with	O
para	O
-	O
substituted	O
derivatives	O
.	O
These	O
analogues	O
when	O
examined	O
for	O
suppressive	O
activity	O
against	O
drug	O
-	O
sensitive	O
lines	O
of	O
Plasmodium	O
berghei	O
in	O
mice	O
were	O
not	O
as	O
active	O
as	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dichlorobenzyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
Ia	O
)	O
.	O
The	O
required	O
substituted	B-MODIFIER
dibenzo	B-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
dioxin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
were	O
prepared	O
by	O
a	O
variety	O
of	O
methods	O
.	O
The	O
diester	O
of	O
5	B-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
27	O
)	O
treated	O
with	O
methanol	B-IUPAC
or	O
sodium	O
azide	O
gave	O
5	B-PARTIUPAC
-	I-PARTIUPAC
methoxymethyl	I-PARTIUPAC
-	I-PARTIUPAC
(	O
29	O
)	O
and	O
5	B-PARTIUPAC
-	I-PARTIUPAC
azidomethyl	I-PARTIUPAC
-	I-PARTIUPAC
(	O
31	O
)	O
2'	B-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
.	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
Hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
was	O
prepared	O
by	O
alkylation	O
of	O
the	O
imidazole	O
13	O
with	O
(	B-IUPAC
2	I-IUPAC
-	I-IUPAC
acetoxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
bromide	I-IUPAC
followed	O
by	O
treatment	O
with	O
methanolic	O
ammonia	O
.	O
The	O
ED	O
(	O
50	O
)	O
values	O
for	O
2beta	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
isoxazoles	I-IUPAC
)	I-IUPAC
that	O
caused	O
locomotor	O
stimulation	O
ranged	O
from	O
0.2	O
to	O
12.8	O
mg	O
/	O
kg	O
.	O
7	B-IUPAC
-	I-IUPAC
Benzyl	I-IUPAC
-	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
3'	I-IUPAC
:	I-IUPAC
4,5	I-IUPAC
]	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
21	O
)	O
had	O
the	O
IC	O
(	O
50	O
)	O
value	O
of	O
330	O
nM	O
for	O
AChE	O
inhibition	O
.	O
The	O
isoindolinylamide	B-IUPAC
side	B-MODIFIER
chain	I-MODIFIER
was	O
tolerated	O
if	O
the	O
5	O
-	O
position	O
was	O
unsubstituted	O
(	O
K	O
(	O
i	O
)	O
of	O
5a	O
=	O
123	O
nM	O
)	O
,	O
otherwise	O
affinity	O
was	O
abolished	O
(	O
5b	O
,	O
c	O
)	O
.	O
In	O
tissue	O
culture	O
assays	O
,	O
22	B-IUPAC
-	I-IUPAC
hydroxycholesterol	I-IUPAC
as	O
well	O
as	O
the	O
side	O
chain	O
modified	O
analogues	O
were	O
potent	O
inhibitors	O
of	O
HMG	O
CoA	O
reductase	O
.	O
The	O
nuclear	O
enzyme	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
facilitates	O
the	O
repair	O
of	O
DNA	O
strand	O
breaks	O
and	O
is	O
implicated	O
in	O
the	O
resistance	O
of	O
cancer	O
cells	O
to	O
certain	O
DNA	O
-	O
damaging	O
agents	O
.	O
Thus	O
,	O
4d	O
is	O
an	O
effective	O
and	O
highly	O
selective	O
inhibitor	O
of	O
calcium	O
chloride	O
-	O
dependent	O
[	O
3H	O
]	O
glutamic	O
acid	O
binding	O
and	O
may	O
be	O
a	O
useful	O
tool	O
for	O
studies	O
of	O
the	O
physiological	O
relevance	O
and	O
pharmacological	O
importance	O
of	O
this	O
binding	O
affinity	O
.	O
High	O
specific	O
activity	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
R	O
)	O
-	O
FIPCT	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
(	O
S	O
)	O
-	O
FIPCT	O
were	O
synthesized	O
in	O
5%	O
radiochemical	O
yield	O
(	O
decay	O
-	O
corrected	O
to	O
end	O
of	O
bombardment	O
(	O
EOB	O
)	O
)	O
by	O
preparation	O
of	O
the	O
precursors	O
2beta	B-IUPAC
-	I-IUPAC
carbo	I-IUPAC
-	I-IUPAC
R	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mesyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorop	I-IUPAC
hen	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
tropane	I-IUPAC
(	O
R	O
-	O
12	O
)	O
and	O
2beta	B-IUPAC
-	I-IUPAC
carbo	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
mesyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propoxy	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorop	I-IUPAC
hen	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
tropane	I-IUPAC
(	O
S	O
-	O
12	O
)	O
followed	O
by	O
treatment	O
with	O
no	O
carrier	O
-	O
added	O
potassium	O
[	O
(	O
18	O
)	O
F	O
]	O
fluoride	O
and	O
kyrptofix	O
K222	O
in	O
acetonitrile	O
.	O
The	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
mesitylimino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogue	B-MODIFIER
trequinsin	O
is	O
a	O
potent	O
antihypertensive	O
agent	O
and	O
displays	O
a	O
hemodynamic	O
profile	O
characteristic	O
of	O
an	O
arteriolar	O
dilator	O
.	O
A	O
series	O
of	O
substituted	B-MODIFIER
dibenzo	B-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
dioxin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
has	O
been	O
synthesized	O
and	O
evaluated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antitumor	O
activity	O
.	O
Also	O
,	O
six	O
of	O
the	O
eight	O
diamidines	O
gave	O
in	O
vitro	O
IC	O
(	O
50	O
)	O
values	O
of	O
88	O
nM	O
or	O
less	O
vs	O
P	O
.	O
Reduction	O
of	O
26	O
+	O
27	O
and	O
31	O
+	O
32	O
with	O
DIBALH	O
afforded	O
(	B-PARTIUPAC
Z	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	B-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylenecyclopropane	I-IUPAC
alcohols	I-IUPAC
14	O
+	O
16	O
and	O
33	O
+	O
34	O
.	O
10h	O
is	O
currently	O
the	O
focus	O
of	O
pharmaceutical	O
and	O
preclinical	O
development	O
.	O
Affinity	O
for	O
brain	O
A1	O
and	O
A2	O
adenosine	O
receptors	O
was	O
determined	O
in	O
binding	O
assays	O
for	O
these	O
and	O
other	O
xanthines	O
with	O
substituents	O
in	O
1	O
-	O
,	O
3	O
-	O
,	O
7	O
-	O
,	O
8	O
-	O
,	O
and	O
9	O
-	O
positions	O
.	O
This	O
is	O
consistent	O
with	O
the	O
binding	O
and	O
activation	O
of	O
CD81	O
and	O
represents	O
a	O
2	O
-	O
fold	O
improvement	O
compared	O
to	O
the	O
clinically	O
prescribed	O
anti	O
-	O
HCV	O
agent	O
,	O
amantidine	O
,	O
in	O
the	O
same	O
concentration	O
range	O
.	O
Results	O
of	O
these	O
studies	O
indicate	O
that	O
,	O
in	O
addition	O
to	O
the	O
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
methyl	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
moiety	B-MODIFIER
,	O
the	O
presence	O
of	O
an	O
acid	O
group	O
and	O
a	O
lipophilic	O
side	O
chain	O
,	O
as	O
well	O
as	O
the	O
spatial	O
relationship	O
of	O
these	O
three	O
functions	O
,	O
is	O
crucial	O
for	O
high	O
binding	O
affinity	O
with	O
LTB4	O
receptors	O
.	O
The	O
novel	O
compounds	O
featured	O
are	O
derived	O
structurally	O
from	O
two	O
key	O
lead	O
structures	O
:	O
2	B-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenoxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	O
21-0041	O
,	O
9	O
)	O
and	O
2	B-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
(	O
NNC	O
90-1515	O
,	O
4	O
)	O
.	O
Importantly	O
,	O
both	O
the	O
locomotor	O
activity	O
and	O
the	O
cocaine	O
discrimination	O
ED	O
(	O
50	O
)	O
values	O
were	O
correlated	O
with	O
the	O
DAT	O
binding	O
but	O
not	O
5	O
-	O
HTT	O
and	O
NET	O
binding	O
.	O
The	O
enantioselectivity	O
was	O
determined	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatographic	O
analysis	O
of	O
the	O
enzymatically	O
formed	O
diastereomeric	O
products	O
.	O
The	O
two	O
isomers	O
display	O
different	O
binding	O
affinities	O
toward	O
dopamine	O
transporters	O
and	O
distinct	O
properties	O
of	O
localization	O
in	O
the	O
striatum	O
area	O
of	O
the	O
brain	O
where	O
the	O
transporters	O
are	O
located	O
.	O
While	O
it	O
is	O
unclear	O
whether	O
virus	O
entry	O
into	O
host	O
cells	O
is	O
directly	O
linked	O
to	O
virus	O
attachment	O
via	O
CD81	O
for	O
HCV	O
,	O
this	O
step	O
in	O
the	O
viral	O
life	O
cycle	O
has	O
recently	O
proven	O
to	O
be	O
an	O
effective	O
point	O
of	O
attack	O
for	O
other	O
viruses	O
including	O
HIV	O
and	O
rhinoviruses	O
.	O
Higher	O
binding	O
affinity	O
for	O
dopamine	O
transporters	O
was	O
observed	O
for	O
3B	O
(	O
Ki	O
=	O
13.87	O
and	O
8.42	O
nM	O
for	O
the	O
analogous	O
rhenium	O
complexes	O
3A	O
,	O
B	O
,	O
respectively	O
)	O
.	O
Reaction	O
of	O
hydroxyl	O
-	O
protected	O
derivatives	O
of	O
hydroxyalkoxyamines	O
(	O
3a	O
,	O
b	O
,	O
c	O
)	O
with	O
either	O
4,6	B-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2,5	I-IUPAC
-	I-IUPAC
diformamidopyrimidine	I-IUPAC
(	O
5	O
)	O
or	O
4,6	B-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
formamidopyrimidine	I-IUPAC
(	O
31	O
)	O
and	O
subsequent	O
cyclization	O
of	O
the	O
resultant	O
6	B-IUPAC
-	I-IUPAC
(	I-IUPAC
alkoxyamino	I-IUPAC
)	I-IUPAC
pyrimidines	I-IUPAC
(	O
6	O
,	O
17	O
,	O
32	O
,	O
35	O
)	O
by	O
heating	O
with	O
diethoxymethyl	O
acetate	O
afforded	O
9	B-IUPAC
-	I-IUPAC
alkoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurines	I-IUPAC
(	O
7	O
,	O
18	O
,	O
33	O
,	O
36	O
)	O
,	O
which	O
were	O
converted	O
subsequently	O
to	O
9	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
hydroxypropoxy	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
9	B-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
propoxy	I-IUPAC
]	I-IUPAC
derivatives	B-MODIFIER
of	O
guanine	O
,	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloropurine	I-IUPAC
,	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
alkoxypurines	I-IUPAC
,	O
2	B-IUPAC
-	I-IUPAC
aminopurine	I-IUPAC
,	O
2,6	B-IUPAC
-	I-IUPAC
diaminopurine	I-IUPAC
,	O
adenine	O
,	O
hypoxanthine	O
,	O
and	O
6	B-IUPAC
-	I-IUPAC
methoxypurine	I-IUPAC
(	O
8	O
,	O
12	O
,	O
13	O
,	O
19-21	O
,	O
23-26	O
,	O
34	O
,	O
37-39	O
)	O
.	O
None	O
of	O
these	O
compounds	O
extended	O
the	O
life	O
span	O
of	O
Plasmodium	O
berghei	O
infected	O
mice	O
or	O
showed	O
significant	O
in	O
vitro	O
inhibition	O
of	O
HGPRT	O
from	O
H	O
.	O
Apyrogenic	O
samples	O
of	O
[	B-IUPAC
3	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
temozolomide	I-IUPAC
(	O
9	O
)	O
and	O
[	B-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
temozolomide	I-IUPAC
(	O
11	O
)	O
,	O
with	O
good	O
chemical	O
and	O
radiochemical	O
purities	O
,	O
have	O
been	O
prepared	O
and	O
used	O
in	O
human	O
PET	O
studies	O
.	O
Many	O
of	O
these	O
derivatives	O
exhibit	O
K	O
(	O
i	O
)	O
values	O
for	O
PARP	O
inhibition	O
&	O
lt	O
;	O
10	O
nM	O
,	O
with	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxymethylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
78	O
,	O
K	O
(	O
i	O
)	O
=	O
1.6	O
nM	O
)	O
being	O
one	O
of	O
the	O
most	O
potent	O
.	O
The	O
affinity	O
of	O
3,5,5	B-IUPAC
'	I-IUPAC
-	I-IUPAC
triphenylimidazolidine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
and	O
3,5,5	B-IUPAC
'	I-IUPAC
-	I-IUPAC
triphenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thioxoimidazolidin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
derivatives	B-MODIFIER
,	O
possessing	O
the	O
1	B-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylurea	I-IUPAC
and	O
1	B-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylthiourea	I-IUPAC
moiety	B-MODIFIER
,	O
respectively	O
,	O
was	O
also	O
evaluated	O
.	O
The	O
significance	O
of	O
their	O
sigma	O
-	O
binding	O
activity	O
in	O
light	O
of	O
their	O
dopaminergic	O
properties	O
is	O
unclear	O
.	O
Previous	O
correlation	O
of	O
fluorescence	O
and	O
NMR	O
data	O
suggested	O
that	O
the	O
11R	O
,	O
11aS	O
and	O
the	O
11S	O
,	O
11aS	O
diastereomers	O
of	O
tomaymycin	O
could	O
bind	O
to	O
DNA	O
in	O
two	O
orientations	O
relative	O
to	O
the	O
covalently	O
modified	O
guanine	O
(	O
Barkley	O
,	O
M	O
.	O
Syntheses	O
of	O
the	O
trans	B-IUPAC
-	I-IUPAC
dihydrodiol	I-IUPAC
derivatives	B-MODIFIER
implicated	O
as	O
the	O
proximate	O
carcinogenic	O
metabolites	O
of	O
the	O
polycyclic	O
hydrocarbons	O
cholanthrene	O
,	O
6	B-IUPAC
-	I-IUPAC
methylcholanthrene	I-IUPAC
,	O
benz	B-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
,	O
and	O
7	B-PARTIUPAC
-	I-PARTIUPAC
and	O
12	B-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
are	O
described	O
.	O
Generally	O
,	O
the	O
divalent	O
linear	O
arrays	O
of	O
the	O
multimeric	O
RGD	O
units	O
bound	O
the	O
ABIR	O
with	O
slightly	O
higher	O
affinity	O
than	O
their	O
monovalent	O
analogues	O
.	O
Some	O
of	O
these	O
analogues	O
displayed	O
weak	O
antagonist	O
properties	O
.	O
The	O
trisubstituted	O
guanidine	O
,	O
N	B-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthyl	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethylphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
methylguanidine	I-IUPAC
(	O
40	O
)	O
and	O
its	O
close	O
analogues	O
showed	O
good	O
in	O
vivo	O
neuroprotection	O
and	O
are	O
potential	O
neuroprotective	O
drug	O
candidates	O
for	O
the	O
treatment	O
of	O
stroke	O
and	O
other	O
neurodegenerative	O
disorders	O
.	O
The	O
expected	O
thermodynamic	O
stability	O
resulting	O
from	O
the	O
preorganization	O
of	O
the	O
pseudosugar	O
rings	O
into	O
a	O
Northern	O
conformation	O
,	O
typical	O
of	O
A	O
-	O
DNA	O
,	O
was	O
evident	O
by	O
the	O
increase	O
in	O
Tm	O
of	O
the	O
corresponding	O
DNA	O
/	O
RNA	O
heteroduplex	O
.	O
In	O
conclusion	O
,	O
TRODAT	O
-	O
1	O
formed	O
at	O
least	O
two	O
diastereomers	O
after	O
complexing	O
with	O
a	O
metal	O
(	O
V	O
)	O
-	O
oxo	O
(	O
M	O
=	O
99mTc	O
,	O
Re	O
)	O
center	O
core	O
.	O
Selected	O
isomeric	O
1	B-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
naphthyridin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
also	O
prepared	O
in	O
order	O
to	O
evaluate	O
the	O
relative	O
contributions	O
of	O
both	O
ring	O
A	O
aza	O
atoms	O
of	O
the	O
related	O
pyrido	B-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
8H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
to	O
the	O
inhibitory	O
activity	O
.	O
The	O
observed	O
relationships	O
between	O
nonquaternary	O
compound	O
structure	O
,	O
reactivation	O
potency	O
,	O
and	O
anti	O
-	O
AChE	O
activity	O
reveal	O
important	O
molecular	O
requirements	O
for	O
high	O
reactivity	O
toward	O
phosphonylated	O
AChE	O
.	O
Conformational	O
studies	O
on	O
30g	O
indicated	O
that	O
the	O
two	O
stable	O
conformers	O
of	O
30g	O
are	O
quite	O
similar	O
to	O
those	O
of	O
CP	O
-	O
99,994	O
.	O
Plutonium	O
excretion	O
after	O
injection	O
of	O
either	O
CAM	O
-	O
HOPO	O
ligand	O
was	O
700%	O
of	O
that	O
for	O
24	O
-	O
h	O
Pu	O
-	O
injected	O
controls	O
,	O
140%	O
of	O
that	O
for	O
mice	O
given	O
the	O
tetracatecholate	O
analogue	O
3,4,3	O
-	O
LICAM	O
(	O
significantly	O
more	O
,	O
p	O
&	O
lt	O
;	O
0.01	O
)	O
,	O
but	O
only	O
80%	O
of	O
that	O
promoted	O
by	O
3,4,3	O
-	O
LIHOPO	O
(	O
significantly	O
less	O
)	O
.	O
This	O
has	O
never	O
been	O
seen	O
for	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
PPP	O
without	O
tropolone	O
pretreatment	O
and	O
might	O
indicate	O
that	O
,	O
in	O
this	O
special	O
case	O
,	O
the	O
catecholic	O
metabolite	O
affects	O
the	O
in	O
vivo	O
pharmacological	O
profile	O
of	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
PPP	O
.	O
A	O
study	O
of	O
ring	O
-	O
expanded	O
analogues	O
of	O
the	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
propananilido	I-IUPAC
)	I-IUPAC
piperidine	I-IUPAC
analgesics	O
has	O
been	O
undertaken	O
in	O
order	O
to	O
evaluate	O
the	O
influence	O
of	O
this	O
structural	O
modification	O
on	O
both	O
analgesic	O
activity	O
and	O
physical	O
-	O
dependence	O
capacity	O
.	O
Using	O
the	O
patch	O
-	O
clamp	O
technique	O
in	O
primary	O
cultures	O
of	O
granule	O
neurons	O
we	O
tested	O
compounds	O
10	O
and	O
21	O
for	O
their	O
ability	O
to	O
modulate	O
currents	O
evoked	O
by	O
KA	O
and	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propionic	I-IUPAC
acid	I-IUPAC
(	O
ATPA	O
)	O
.	O
A	O
series	O
of	O
28	O
new	O
pyrrolo	B-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amines	I-IUPAC
,	O
pyrimido	B-IUPAC
[	I-IUPAC
4	I-IUPAC
,	I-IUPAC
5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amines	I-IUPAC
,	O
and	O
tetrahydropyrimido	B-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
indole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amines	I-IUPAC
was	O
synthesized	O
and	O
their	O
adenosine	O
receptor	O
affinity	O
determined	O
in	O
radioligand	O
binding	O
assays	O
at	O
rat	O
A	O
(	O
1	O
)	O
and	O
A	O
(	O
2A	O
)	O
adenosine	O
receptors	O
(	O
ARs	O
)	O
.	O
All	O
DTACs	O
and	O
indenes	O
were	O
competitive	O
inhibitors	O
of	O
[	O
3H	O
]	O
estradiol	O
binding	O
in	O
the	O
immature	O
rat	O
uterine	O
cytosol	O
receptor	O
assay	O
,	O
with	O
relative	O
binding	O
affinities	O
of	O
0.1-3.6%	O
of	O
estradiol	O
.	O
The	O
isomeric	O
4	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
hydroxyphenyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinolines	I-IUPAC
,	O
the	O
N	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
derivative	B-MODIFIER
of	O
the	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
isomer	B-MODIFIER
,	O
and	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydroisoquinoline	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
dopamine	O
D	O
-	O
1	O
antagonist	O
activity	O
.	O
These	O
compounds	O
show	O
promising	O
activity	O
for	O
further	O
testing	O
on	O
in	O
vivo	O
models	O
.	O
Useful	O
activity	O
in	O
the	O
5,10	B-IUPAC
-	I-IUPAC
dideaza	I-IUPAC
series	B-MODIFIER
was	O
only	O
observed	O
for	O
5,10	B-IUPAC
-	I-IUPAC
dideazaaminopterin	I-IUPAC
and	O
its	O
10	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
analogue	B-MODIFIER
.	O
A	O
single	O
subcutaneous	O
administration	O
of	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
to	O
streptozocin	O
-	O
treated	O
rats	O
lowered	O
circulating	O
glucose	O
levels	O
for	O
a	O
prolonged	O
period	O
(	O
t	O
(	O
1/2	O
)	O
=	O
30	O
h	O
)	O
.	O
Both	O
43	O
(	O
ED	O
(	O
50	O
)	O
=	O
150	O
micromol	O
/	O
kg	O
)	O
and	O
44	O
(	O
ED	O
(	O
50	O
)	O
=	O
220	O
micromol	O
/	O
kg	O
)	O
showed	O
anticonvulsant	O
effects	O
,	O
and	O
this	O
effect	O
of	O
43	O
was	O
shown	O
to	O
reside	O
in	O
the	O
(	O
R	O
)	O
-	O
(	O
+	O
)	O
-	O
enantiomer	O
,	O
45	O
(	O
ED	O
(	O
50	O
)	O
=	O
44	O
micromol	O
/	O
kg	O
)	O
.	O
Compound	O
8	O
,	O
a	O
pyrrolo	O
analogue	O
of	O
7	O
,	O
was	O
devoid	O
of	O
inotropic	O
activity	O
,	O
while	O
the	O
pyrido	B-IUPAC
analogues	B-MODIFIER
9	O
were	O
equiactive	O
to	O
7	O
and	O
amrinone	O
.	O
A	O
series	O
of	O
(	B-MODIFIER
+	I-MODIFIER
)	I-MODIFIER
-	I-MODIFIER
3	I-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
17	B-IUPAC
-	I-IUPAC
methylmorphinans	I-IUPAC
,	O
which	O
are	O
structurally	O
similar	O
to	O
1	O
but	O
are	O
either	O
not	O
expected	O
to	O
be	O
metabolized	O
to	O
2	O
or	O
might	O
do	O
so	O
at	O
a	O
reduced	O
rate	O
,	O
as	O
compared	O
to	O
1	O
,	O
were	O
prepared	O
.	O
Carbamoylation	O
of	O
the	O
N	O
-	O
terminus	O
as	O
in	O
des	O
-	O
AA	O
(	O
1,2,5	O
)	O
-	O
[	O
DTrp	O
(	O
8	O
)	O
,	O
IAmp	O
(	O
9	O
)	O
,	O
Tyr	O
(	O
11	O
)	O
]	O
-	O
Cbm	O
-	O
SRIF	O
(	O
27	O
)	O
increased	O
affinity	O
slightly	O
as	O
well	O
as	O
improved	O
selectivity	O
.	O
These	O
structure	O
-	O
affinity	O
findings	O
were	O
exploited	O
to	O
produce	O
nicotinamides	O
(	O
e.g.	O
13ii	O
and	O
25x	O
)	O
and	O
pyrazolo	B-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridines	I-IUPAC
(	O
e.g.	O
37f	O
and	O
37y	O
)	O
ligands	O
with	O
nanomolar	O
affinity	O
at	O
the	O
alpha	O
1	O
-	O
AR	O
subtype	O
prevalent	O
in	O
the	O
human	O
lower	O
urinary	O
tract	O
(	O
pA2	O
values	O
:	O
8.8	O
,	O
10.7	O
,	O
9.3	O
,	O
and	O
9.9	O
,	O
respectively	O
)	O
and	O
displaying	O
2-3	O
orders	O
of	O
magnitude	O
selectivity	O
over	O
the	O
alpha	O
1D	O
-	O
AR	O
.	O
Further	O
molecular	O
modifications	O
involve	O
the	O
pendant	O
phenyl	O
ring	O
as	O
well	O
as	O
quaternary	O
amine	O
compounds	O
.	O
In	O
contrast	O
,	O
the	O
compounds	O
with	O
a	O
phenethyl	O
ester	O
group	O
,	O
which	O
exhibited	O
antagonist	O
activity	O
(	O
IC50	O
=	O
10	O
(	O
-	O
5	O
)	O
-	O
10	O
(	O
-	O
7	O
)	O
M	O
range	O
)	O
on	O
GPILSM	O
,	O
were	O
devoid	O
of	O
cardiac	O
agonist	O
activity	O
on	O
GPLA	O
.	O
Of	O
the	O
four	O
compounds	O
examined	O
,	O
only	O
compound	O
2	O
showed	O
significant	O
direct	O
activity	O
on	O
beta1	O
-	O
and	O
beta2	O
-	O
adrenergic	O
receptors	O
.	O
The	O
intrinsic	O
activity	O
of	O
the	O
compounds	O
was	O
evaluated	O
by	O
measuring	O
their	O
effect	O
on	O
VIP	O
-	O
stimulated	O
cAMP	O
production	O
in	O
GH4ZD10	O
cells	O
stably	O
transfected	O
with	O
the	O
5	O
-	O
HT1A	O
receptor	O
.	O
The	O
major	O
structural	O
differences	O
between	O
2a	O
and	O
(	O
3S	O
,	O
4R	O
)	O
-	O
3	O
are	O
that	O
2a	O
possesses	O
a	O
different	O
absolute	O
stereochemistry	O
and	O
has	O
an	O
ethylene	O
bridge	O
not	O
present	O
in	O
3	O
.	O
To	O
develop	O
potential	O
antitumor	O
agents	O
directed	O
toward	O
HER2	O
/	O
ErbB2	O
overexpression	O
in	O
cancer	O
,	O
we	O
have	O
designed	O
inhibitors	O
of	O
the	O
recognition	O
between	O
the	O
phosphotyrosine	O
of	O
the	O
receptor	O
and	O
the	O
SH2	O
domain	O
of	O
the	O
adaptor	O
protein	O
Grb2	O
.	O
Glycosylation	O
of	O
ethyl	B-IUPAC
3	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
(	O
3	O
)	O
and	O
3	B-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
3	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
4	O
)	O
with	O
poly	O
-	O
O	O
-	O
acetylated	O
sugars	O
via	O
an	O
acid	O
-	O
catalyzed	O
fusion	O
method	O
afforded	O
the	O
corresponding	O
ethyl	B-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
and	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
pyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
substituted	B-MODIFIER
nucleosides	I-MODIFIER
5	I-MODIFIER
and	O
7	B-MODIFIER
,	O
respectively	O
.	O
The	O
compounds	O
are	O
related	O
to	O
Lu	O
28-179	O
(	O
1'	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
spiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidine	I-IUPAC
]	I-IUPAC
)	O
that	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
selective	O
sigma	O
2	O
ligand	O
with	O
affinity	O
in	O
the	O
subnanomolar	O
range	O
.	O
Substitution	O
at	O
position	O
1	O
or	O
3	O
with	O
methyl	O
or	O
fluorine	O
atoms	O
always	O
led	O
to	O
more	O
active	O
compounds	O
.	O
N1	B-IUPAC
-	I-IUPAC
Allylchlorpropamide	I-IUPAC
3	O
was	O
,	O
as	O
expected	O
,	O
a	O
potent	O
inhibitor	O
of	O
hepatic	O
AlDH	O
in	O
rats	O
,	O
as	O
indicated	O
by	O
the	O
4	O
-	O
fold	O
increase	O
in	O
the	O
levels	O
of	O
ethanol	O
-	O
derived	O
blood	O
acetaldehyde	O
relative	O
to	O
that	O
elicited	O
by	O
chlorpropamide	O
itself	O
.	O
coli	O
thymidine	O
kinase	O
(	O
TK	O
)	O
,	O
and	O
of	O
yeast	O
hexokinase	O
(	O
HK	O
)	O
and	O
rat	O
KH	O
I	O
,	O
II	O
,	O
and	O
III	O
isozymes	O
.	O
Hence	O
rotational	O
restriction	O
of	O
the	O
side	O
chain	O
did	O
not	O
interfere	O
with	O
the	O
initial	O
FPGS	O
-	O
catalyzed	O
reaction	O
and	O
indeed	O
seemed	O
to	O
facilitate	O
it	O
,	O
but	O
the	O
ensuing	O
gamma	O
-	O
glutamyl	O
adduct	O
was	O
no	O
longer	O
an	O
efficient	O
substrate	O
for	O
the	O
enzyme	O
.	O
All	O
these	O
imidazole	O
nucleosides	O
were	O
tested	O
in	O
HeLa	O
cell	O
cultures	O
against	O
type	O
1	O
herpes	O
simplex	O
and	O
vesicular	O
stomatitis	O
viruses	O
.	O
We	O
describe	O
a	O
new	O
versatile	O
synthesis	O
of	O
this	O
homologue	O
of	O
AMPA	O
and	O
the	O
synthesis	O
of	O
compound	O
10	O
.	O
The	O
prototype	O
of	O
such	O
a	O
compound	O
was	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
indole	I-IUPAC
,	O
11a	O
(	O
code	O
no	O
.	O
The	O
polyamine	O
spacer	O
units	O
ranged	O
from	O
generic	O
(	O
4,4	B-IUPAC
-	I-IUPAC
triamine	I-IUPAC
,	O
4,3	B-IUPAC
-	I-IUPAC
triamine	I-IUPAC
,	O
and	O
diaminooctane	O
)	O
spacers	O
to	O
more	O
exotic	O
[	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxy	I-IUPAC
)	I-IUPAC
ethanoxy	I-IUPAC
-	I-IUPAC
containing	B-MODIFIER
diamine	B-IUPAC
,	O
hydroxylated	B-MODIFIER
4,3	B-IUPAC
-	I-IUPAC
triamine	I-IUPAC
,	O
and	O
cyclohexylene	O
-	O
containing	O
triamine	O
]	O
spacers	O
.	O
A	O
number	O
of	O
conjugates	O
of	O
5	B-IUPAC
-	I-IUPAC
fluoroorotic	I-IUPAC
acid	I-IUPAC
and	O
peptides	O
were	O
synthesized	O
using	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethoxy	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydroquinoline	I-IUPAC
as	O
the	O
coupling	O
agent	O
.	O
1c	O
and	O
FU	O
inhibited	O
the	O
growth	O
of	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
in	O
culture	O
at	O
a	O
concentration	O
of	O
5	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O
The	O
relationship	O
between	O
the	O
key	O
PAF	O
antagonist	O
pharmacophores	O
of	O
2	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
,	O
a	O
triazolothienodiazepine	O
(	O
WEB2170	O
)	O
,	O
and	O
a	O
pyrrolothiazolidine	O
(	O
RP	O
-	O
52,770	O
)	O
is	O
discussed	O
.	O
The	O
formation	O
of	O
a	O
gamma	O
-	O
lactone	O
ring	O
in	O
the	O
side	O
chain	O
,	O
4	B-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
butan	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
olid	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
ammonium	I-IUPAC
chloride	I-IUPAC
(	O
6	O
)	O
,	O
resulted	O
in	O
a	O
small	O
decrease	O
in	O
activity	O
.	O
Optimization	O
of	O
substituents	O
at	O
these	O
two	O
positions	O
identified	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cyclohexyladenine	I-IUPAC
(	O
12	O
)	O
,	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cycloheptyladenine	I-IUPAC
(	O
19	O
)	O
,	O
and	O
2	B-IUPAC
-	I-IUPAC
phenylamino	I-IUPAC
-	I-IUPAC
N	I-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
endo	I-IUPAC
-	I-IUPAC
norbornyladenine	I-IUPAC
(	O
21	O
)	O
as	O
potent	O
A	O
(	O
3	O
)	O
AR	O
ligands	O
with	O
K	O
(	O
i	O
)	O
values	O
of	O
51	O
,	O
42	O
,	O
and	O
37	O
nM	O
,	O
respectively	O
,	O
with	O
30-200	O
-	O
fold	O
selectivity	O
in	O
comparison	O
to	O
A	O
(	O
1	O
)	O
and	O
A	O
(	O
2A	O
)	O
ARs	O
.	O
In	O
Chinese	O
hamster	O
ovary	O
cells	O
stably	O
transfected	O
with	O
human	O
A2B	O
receptor	O
cDNA	O
,	O
inhibition	O
of	O
agonist	O
-	O
induced	O
cyclic	O
AMP	O
production	O
was	O
measured	O
.	O
Placement	O
of	O
the	O
epoxyalkyl	O
group	O
at	O
the	O
carboxy	O
terminus	O
led	O
to	O
potent	O
rapid	O
inactivation	O
.	O
Evaluation	O
of	O
minimum	O
inhibitory	O
concentrations	O
of	O
peptide	B-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
conjugates	B-MODIFIER
suggest	O
that	O
these	O
conjugates	O
enter	O
C	O
.	O
Of	O
the	O
other	O
agents	O
,	O
4	O
exhibited	O
the	O
most	O
favorable	O
pharmaceutical	O
profile	O
:	O
the	O
agent	O
has	O
appropriate	O
stability	O
in	O
the	O
presence	O
of	O
tumor	O
cells	O
and	O
rat	O
liver	O
microsomes	O
and	O
achieves	O
rapid	O
ingress	O
into	O
cell	O
nuclei	O
where	O
the	O
putative	O
molecular	O
target	O
is	O
located	O
.	O
l	I-IUPAC
-	I-IUPAC
phenylalanine	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
complex	B-MODIFIER
(	O
5	O
)	O
,	O
1	B-IUPAC
-	I-IUPAC
boraadamantane	I-IUPAC
.	I-IUPAC
In	O
a	O
preliminary	O
behavioral	O
study	O
on	O
rats	O
(	O
+	O
)	O
-	O
14b	O
,	O
and	O
to	O
a	O
greater	O
extent	O
(	O
+	O
)	O
-	O
15b	O
,	O
promoted	O
episodes	O
of	O
intense	O
grooming	O
,	O
thus	O
indicating	O
that	O
they	O
act	O
as	O
central	O
D1	O
agonists	O
.	O
The	O
antiviral	O
activity	O
of	O
TFPe	O
-	O
dUrd	O
was	O
determined	O
in	O
cell	O
culture	O
against	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
,	O
herpes	O
simplex	O
virus	O
type	O
2	O
(	O
HSV	O
-	O
2	O
)	O
,	O
and	O
vaccinia	O
virus	O
and	O
compared	O
concurrently	O
with	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bromovinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
5	B-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
and	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoromethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
.	O
The	O
metabolite	O
-	O
corrected	O
blood	O
half	O
-	O
life	O
was	O
41	O
min	O
.	O
These	O
conjugates	O
exhibited	O
very	O
strong	O
antibacterial	O
activity	O
in	O
vitro	O
against	O
Gram	O
-	O
negative	O
bacterial	O
pathogens	O
including	O
Pseudomonas	O
aeruginosa	O
,	O
Stenotrophomonas	O
maltophilia	O
,	O
Escherichia	O
coli	O
,	O
Klebsiella	O
pneumoniae	O
,	O
and	O
Serratia	O
marcescens	O
.	O
In	O
the	O
2,6	O
series	O
activity	O
against	O
both	O
microsomal	O
systems	O
varied	O
only	O
over	O
a	O
relatively	O
narrow	O
range	O
,	O
6	B-IUPAC
-	I-IUPAC
allyloxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyacetophenone	I-IUPAC
(	O
19	O
)	O
being	O
the	O
most	O
potent	O
inhibitor	O
.	O
Boron	O
tribromide	O
demethylation	O
afforded	O
the	O
racemic	O
ring	O
-	O
fluorinated	O
norepinephrines	O
.	O
The	O
site	O
of	O
glycosylation	O
and	O
anomeric	O
configuration	O
of	O
6a	O
and	O
6c	O
were	O
assigned	O
on	O
the	O
basis	O
of	O
spectral	O
studies	O
as	O
well	O
as	O
conversion	O
to	O
allopurinol	O
ribonucleoside	O
,	O
whereas	O
the	O
structural	O
assignment	O
of	O
6b	O
was	O
made	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
.	O
These	O
glucagon	O
analogues	O
have	O
been	O
made	O
by	O
either	O
deleting	O
or	O
substituting	O
hydrophobic	O
groups	O
,	O
hydrophilic	O
groups	O
,	O
aromatic	O
amino	O
acids	O
,	O
or	O
a	O
D	O
-	O
phenylalanine	O
residue	O
at	O
this	O
position	O
.	O
The	O
very	O
potent	O
AMPA	O
agonist	O
effect	O
of	O
7f	O
(	O
IC50	O
=	O
0.15	O
+	O
/	O
-	O
0.03	O
microM	O
;	O
EC50	O
=	O
1.7	O
+	O
/	O
-	O
0	O
.	O
Several	O
N	B-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamic	I-IUPAC
acids	I-IUPAC
were	O
synthesized	O
also	O
in	O
the	O
same	O
manner	O
starting	O
with	O
the	O
requisite	O
p	B-IUPAC
-	I-IUPAC
phenylenediamines	I-IUPAC
.	O
Reaction	O
of	O
2	O
with	O
ethylene	O
oxide	O
resulted	O
in	O
a	O
mixture	O
of	O
two	O
compounds	O
,	O
the	O
2,4	B-IUPAC
-	I-IUPAC
dinitroimidazole	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ethanol	I-IUPAC
(	O
4	O
)	O
and	O
2,3	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
nitroimidazo	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
oxazole	I-IUPAC
(	O
5	O
)	O
.	O
For	O
derivatives	O
unsubstituted	O
at	O
the	O
benzene	O
ring	O
,	O
the	O
highest	O
activity	O
was	O
obtained	O
for	O
the	O
9	B-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
derivative	B-MODIFIER
rac	O
-	O
20	O
,	O
previously	O
prepared	O
by	O
our	O
group	O
.	O
They	O
were	O
tested	O
in	O
radioligand	O
binding	O
assays	O
on	O
sigma	O
(	O
[	O
3H	O
]	O
DTG	O
and	O
[	O
3H	O
]	O
-	O
(	O
+	O
)	O
-	O
pentazocine	O
)	O
,	O
D	O
-	O
2	O
dopaminergic	O
,	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT2	O
serotonergic	O
,	O
and	O
PCP	O
(	O
phencyclidine	O
)	O
receptors	O
.	O
Judging	O
from	O
the	O
investigation	O
of	O
selected	O
compounds	O
,	O
it	O
appears	O
that	O
they	O
are	O
also	O
potent	O
at	O
human	O
A	O
(	O
1	O
)	O
ARs	O
and	O
selective	O
not	O
only	O
versus	O
A	O
(	O
2A	O
)	O
ARs	O
but	O
also	O
highly	O
selective	O
versus	O
A	O
(	O
2B	O
)	O
and	O
A	O
(	O
3	O
)	O
ARs	O
.	O
The	O
most	O
potent	O
compound	O
of	O
the	O
series	O
was	O
(	B-IUPAC
1S	I-IUPAC
,	I-IUPAC
2R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
[	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxoethyl	I-IUPAC
]	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
cyclohexanecarboxylic	I-IUPAC
acid	I-IUPAC
(	O
21a	O
)	O
with	O
an	O
IC50	O
value	O
of	O
7.0	O
nM	O
compared	O
with	O
the	O
value	O
of	O
3.0	O
nM	O
for	O
captopril	O
.	O
cruzi	O
.	O
In	O
this	O
study	O
we	O
designed	O
,	O
prepared	O
,	O
and	O
analyzed	O
a	O
water	O
-	O
soluble	O
,	O
long	O
-	O
acting	O
insulin	O
derivative	O
whose	O
protracted	O
action	O
in	O
vivo	O
is	O
based	O
on	O
a	O
new	O
principle	O
rather	O
than	O
on	O
slower	O
absorption	O
rates	O
of	O
suspended	O
insulin	O
formulations	O
.	O
It	O
is	O
suggested	O
that	O
different	O
conformations	O
of	O
the	O
5	O
-	O
HT	O
-	O
receptor	O
agonists	O
(	B-IUPAC
1R	I-IUPAC
,	I-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propylcyclopropylamine	I-IUPAC
[	O
(	O
1R	O
,	O
2S	O
)	O
-	O
4	O
]	O
and	O
its	O
3	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
isomer	B-MODIFIER
(	O
1R	O
,	O
2S	O
)	O
-	O
5	O
are	O
able	O
to	O
activate	O
5	O
-	O
HT	O
receptors	O
.	O
gondii	O
)	O
were	O
compared	O
.	O
Studies	O
have	O
now	O
shown	O
that	O
exo	O
-	O
active	O
-	O
site	O
-	O
directed	O
reagents	O
can	O
act	O
as	O
isozyme	O
-	O
or	O
species	O
-	O
selective	O
enzyme	O
inhibitors	O
.	O
The	O
new	O
derivatives	O
(	O
1c	O
-	O
g	O
)	O
and	O
also	O
the	O
known	O
diethyl	O
ester	O
of	O
1a	O
(	O
1b	O
)	O
were	O
tested	O
for	O
their	O
inhibition	O
of	O
purified	O
L1210	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
for	O
their	O
inhibition	O
of	O
the	O
growth	O
of	O
L1210	O
cells	O
in	O
culture	O
.	O
Replacement	O
of	O
the	O
methyl	O
with	O
hydrophilic	O
substituents	O
on	O
the	O
benzylic	O
carbon	O
lowered	O
affinity	O
.	O
Stannic	O
chloride	O
catalyzed	O
condensation	O
of	O
pertrimethylsilyl	O
ketoaglycon	O
4a	O
with	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
chloromethoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyloxy	I-IUPAC
)	I-IUPAC
ethane	I-IUPAC
to	O
give	O
ketonucleoside	O
6,7	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
p	I-IUPAC
-	I-IUPAC
toluoyloxy	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
9a	O
)	O
was	O
followed	O
by	O
deprotection	O
to	O
6,7	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
9b	O
)	O
and	O
then	O
reduction	O
to	O
the	O
racemic	O
acyclic	O
pentostatin	O
analogue	O
(	B-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
diazepin	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
ol	I-IUPAC
(	O
2	O
)	O
.	O
The	O
greatest	O
improvement	O
in	O
FT	O
inhibitory	O
potency	O
was	O
observed	O
for	O
the	O
Tic	O
derivative	O
(	O
IC50	O
=	O
1	O
nM	O
)	O
;	O
however	O
,	O
this	O
compound	O
was	O
ineffective	O
in	O
blocking	O
oncogenic	O
Ras	O
-	O
induced	O
transformation	O
of	O
NIH	O
-	O
3T3	O
fibroblast	O
cells	O
.	O
Because	O
of	O
its	O
decreased	O
receptor	O
-	O
binding	O
affinity	O
,	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
evades	O
receptor	O
-	O
mediated	O
endocytosis	O
and	O
degradation	O
and	O
,	O
hence	O
,	O
persists	O
for	O
a	O
long	O
period	O
in	O
the	O
circulation	O
.	O
A	O
similar	O
dehydration	O
of	O
the	O
precursor	O
tetraacetyl	B-IUPAC
derivative	B-MODIFIER
of	O
4	O
gave	O
the	O
corresponding	O
carbonitrile	O
,	O
which	O
on	O
deprotection	O
and	O
subsequent	O
treatment	O
with	O
hydroxylamine	O
furnished	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
benzyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylpyrazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carboxamidoxime	I-IUPAC
(	O
13	O
)	O
.	O
3	B-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
(	O
ortho	B-IUPAC
-	O
Substituted	B-MODIFIER
phenyl	B-IUPAC
)	O
piperazin	B-PARTIUPAC
-	I-PARTIUPAC
1	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
]	I-PARTIUPAC
propylamines	I-PARTIUPAC
were	O
derivatized	O
with	O
N	B-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
anthranilamides	I-IUPAC
,	O
nicotinamides	O
,	O
as	O
well	O
as	O
carboxamides	O
of	O
quinoline	O
,	O
1,8	B-IUPAC
-	I-IUPAC
naphthyridine	I-IUPAC
,	O
pyrazolo	B-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
,	O
isoxazolo	B-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
,	O
imidazo	B-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
,	O
and	O
pyrazolo	B-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
.	O
A	O
variety	O
of	O
mesoionic	O
xanthines	O
including	O
mesoionic	B-MODIFIER
thiazolo	B-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
,	O
benzothiazolopyrimidines	B-IUPAC
,	O
and	O
1,3,4	B-IUPAC
-	I-IUPAC
thiadiazolo	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
were	O
antagonists	O
of	O
A1	O
-	O
adenosine	O
receptors	O
(	O
inhibition	O
of	O
binding	O
of	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
cyclohexyladenosine	I-IUPAC
)	O
and	O
A2	O
-	O
adenosine	O
receptors	O
(	O
inhibition	O
of	O
2	B-IUPAC
-	I-IUPAC
chloroadenosine	I-IUPAC
-	O
elicited	O
accumulations	O
of	O
cyclic	O
AMP	O
)	O
in	O
brain	O
tissue	O
.	O
Three	O
derivatives	O
(	O
5g	O
,	O
i	O
,	O
k	O
)	O
show	O
a	O
hypoxic	O
cytotoxicity	O
ratio	O
(	O
HCR	O
)	O
&	O
gt	O
;	O
or	O
=	O
200	O
,	O
better	O
than	O
that	O
of	O
tirapazamine	O
(	O
HCR	O
=	O
75	O
)	O
in	O
V79	O
cells	O
.	O
Catechol	O
estrogens	O
are	O
implicated	O
as	O
possible	O
causative	O
agents	O
in	O
estrogen	O
-	O
induced	O
tumorigenesis	O
.	O
Following	O
metabolism	O
of	O
2	O
by	O
rat	O
liver	O
microsomes	O
the	O
predicted	O
formation	O
of	O
4,4,4	B-IUPAC
-	I-IUPAC
trifluorocrotonaldehyde	I-IUPAC
(	O
5	O
)	O
was	O
confirmed	O
by	O
isolation	O
and	O
identification	O
,	O
by	O
mass	O
spectrometry	O
,	O
of	O
its	O
dinitrophenylhydrazone	O
.	O
Noteworthy	O
,	O
all	O
compounds	O
within	O
the	O
series	O
induced	O
elongations	O
in	O
K562	O
cells	O
similar	O
to	O
vinblastine	O
-	O
treated	O
cells	O
.	O
These	O
compounds	O
will	O
serve	O
as	O
templates	O
in	O
the	O
design	O
of	O
still	O
further	O
sigma	O
-	O
2	O
subtype	O
selective	O
ligands	O
.	O
A	O
series	O
of	O
thieno	B-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
oxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
thieno	B-IUPAC
[	I-IUPAC
1,3	I-IUPAC
]	I-IUPAC
thiazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
were	O
synthesized	O
and	O
investigated	O
as	O
inhibitors	O
of	O
the	O
alpha	O
/	O
beta	O
hydrolases	O
cholesterol	O
esterase	O
(	O
CEase	O
)	O
and	O
acetylcholinesterase	O
(	O
AChE	O
)	O
.	O
A	O
series	O
of	O
new	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
and	O
uridine	B-IUPAC
compounds	B-MODIFIER
(	O
11	O
,	O
16	O
)	O
was	O
synthesized	O
by	O
the	O
regiospecific	O
addition	O
of	O
HOI	O
to	O
the	O
vinyl	O
substituent	O
of	O
5	B-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
10a	O
)	O
,	O
5	B-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
10b	O
)	O
,	O
5	B-IUPAC
-	I-IUPAC
vinyluridine	I-IUPAC
(	O
10c	O
)	O
,	O
and	O
(	B-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
iodovinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
4b	O
)	O
.	O
The	O
5	B-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
derivatives	B-MODIFIER
were	O
more	O
efficient	O
as	O
sensitizers	O
than	O
the	O
4	B-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
derivatives	B-MODIFIER
,	O
and	O
the	O
sensitizing	O
efficiency	O
of	O
this	O
class	O
of	O
agents	O
was	O
found	O
to	O
have	O
significant	O
correlation	O
with	O
their	O
partition	O
coefficients	O
.	O
(	O
3S	O
,	O
4R	O
)	O
-	O
4	O
-	O
(	O
4	O
-	O
Fluorophenyl	O
)	O
-	O
3	O
-	O
[	O
[	O
3,4	O
-	O
(	O
methylenedioxy	O
)	O
phenoxy	O
]	O
methyl	O
]	O
piperidine	O
[	O
(	O
3S	O
,	O
9R	O
)	O
-	O
3	O
,	O
paroxetine	O
]	O
is	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
used	O
as	O
an	O
antidepressant	O
in	O
humans	O
.	O
Methyl	B-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isothiocyanatomethyl	I-IUPAC
)	I-IUPAC
thiazole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
and	O
methyl	B-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
isothiocyanatomethyl	I-IUPAC
)	I-IUPAC
selenazole	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbamate	I-IUPAC
have	O
been	O
prepared	O
via	O
chemical	O
transformations	O
involving	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloromethyl	I-IUPAC
)	I-IUPAC
thiazole	I-IUPAC
(	O
1	O
)	O
and	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
chloromethyl	I-IUPAC
)	I-IUPAC
selenazole	I-IUPAC
(	O
2	O
)	O
,	O
respectively	O
,	O
as	O
starting	O
materials	O
.	O
A	O
series	O
of	O
unsaturated	O
analogues	O
of	O
nucleosides	O
were	O
prepared	O
and	O
their	O
cytotoxic	O
,	O
antitumor	O
,	O
and	O
antiviral	O
activities	O
were	O
investigated	O
.	O
Both	O
analogues	O
were	O
evaluated	O
in	O
vitro	O
as	O
inhibitors	O
of	O
DHFRs	O
from	O
(	O
recombinant	O
)	O
human	O
,	O
human	O
CCRF	O
-	O
CEM	O
cells	O
,	O
and	O
Lactobacillus	O
casei	O
.	O
No	O
intermediates	O
were	O
detected	O
in	O
the	O
incubation	O
mixture	O
.	O
The	O
compound	O
inhibited	O
(	O
IC50	O
=	O
20	O
nM	O
)	O
the	O
conversion	O
of	O
[	O
14C	O
]	O
formate	O
to	O
[	B-IUPAC
14C	I-IUPAC
]	I-IUPAC
-	I-IUPAC
formylglycinamide	I-IUPAC
ribonucleotide	I-IUPAC
by	O
MOLT	O
-	O
4	O
cells	O
in	O
culture	O
.	O
Our	O
results	O
show	O
dihydropyrimidines	B-IUPAC
3	O
are	O
significantly	O
more	O
potent	O
than	O
corresponding	O
2	B-IUPAC
-	I-IUPAC
heteroalkyl	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyrimidines	I-IUPAC
2	O
and	O
only	O
slightly	O
less	O
potent	O
than	O
similarly	O
substituted	B-MODIFIER
2	B-IUPAC
-	I-IUPAC
heteroalkyl	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyridines	I-IUPAC
4	O
and	O
5	O
.	O
Selectivity	O
at	O
the	O
receptor	O
subclasses	O
was	O
examined	O
by	O
performing	O
an	O
A2	O
adenosine	O
receptor	O
affinity	O
assay	O
with	O
[	O
3H	O
]	O
CGS	O
21680	O
.	O
Studies	O
indicate	O
that	O
there	O
is	O
now	O
a	O
cis	O
-	O
amide	O
bond	O
present	O
which	O
redirects	O
the	O
carboxylate	O
toward	O
the	O
pharmacophoric	O
gem	O
-	O
dimethyl	O
groups	O
.	O
With	O
the	O
exception	O
of	O
II	O
and	O
III	O
,	O
all	O
the	O
other	O
analogs	O
had	O
very	O
low	O
intrinsic	O
activities	O
,	O
per	O
se	O
.	O
The	O
growth	O
-	O
promoting	O
ability	O
of	O
each	O
was	O
evaluated	O
with	O
the	O
siderophore	O
biosynthesis	O
mutant	O
Shigella	O
flexneri	O
SA240	O
(	O
SA	O
100	O
iucD	O
:	O
Tn5	O
)	O
.	O
d	O
.	O
Similarly	O
,	O
they	O
also	O
showed	O
improved	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
(	O
1.5-5	O
-	O
fold	O
)	O
,	O
and	O
this	O
activity	O
was	O
prevented	O
by	O
co	O
-	O
incubation	O
with	O
thymidine	O
.	O
[	B-IUPAC
125I	I-IUPAC
]	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
Azido	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
18,19,20	I-IUPAC
-	I-IUPAC
trinorprostaglandin	I-IUPAC
F2	I-IUPAC
alpha	I-IUPAC
was	O
utilized	O
in	O
a	O
preliminary	O
photoaffinity	O
cross	O
-	O
linking	O
experiment	O
.	O
Treatment	O
of	O
6	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
'	I-IUPAC
-	I-IUPAC
bipyridine	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thiol	I-IUPAC
(	O
59	O
)	O
with	O
ethyl	B-IUPAC
bromoacetate	B-IUPAC
and	O
ethyl	B-IUPAC
bromodifluoroacetate	B-IUPAC
gave	O
pyridothiazinones	O
60	O
and	O
61	O
,	O
respectively	O
.	O
Against	O
the	O
EO771	O
mammary	O
adenocarcinoma	O
in	O
mice	O
,	O
6	O
produced	O
greater	O
antitumor	O
effect	O
than	O
MTX	O
.	O
These	O
observations	O
of	O
good	O
brain	O
penetration	O
and	O
high	O
affinity	O
and	O
selectivity	O
for	O
D	O
-	O
2	O
receptors	O
indicate	O
that	O
the	O
corresponding	O
iodine	O
-	O
123	O
-	O
labeled	O
benzamide	O
may	O
be	O
a	O
useful	O
ligand	O
for	O
the	O
noninvasive	O
visualization	O
study	O
of	O
dopamine	O
D	O
-	O
2	O
receptor	O
sites	O
in	O
vivo	O
by	O
single	O
photon	O
emission	O
computed	O
tomography	O
.	O
The	O
length	O
of	O
the	O
intermediate	O
side	O
chain	O
between	O
the	O
catechol	O
and	O
imidazoline	O
ring	O
or	O
the	O
amine	O
of	O
the	O
ethylenediamine	O
segment	O
was	O
shown	O
to	O
affect	O
the	O
adrenergic	O
activity	O
.	O
The	O
structure	O
-	O
activity	O
relationship	O
studies	O
on	O
the	O
binding	O
affinity	O
and	O
the	O
inhibition	O
of	O
AII	O
-	O
induced	O
pressor	O
response	O
suggested	O
that	O
straight	O
chains	O
of	O
a	O
certain	O
length	O
(	O
e.g.	O
,	O
ethoxy	O
groups	O
,	O
ethyl	O
groups	O
)	O
were	O
the	O
best	O
as	O
substituents	O
at	O
the	O
2	O
-	O
position	O
and	O
that	O
their	O
steric	O
factors	O
,	O
lipophilicity	O
,	O
and	O
electronic	O
effects	O
affected	O
the	O
potency	O
of	O
the	O
AII	O
antagonistic	O
action	O
.	O
Compounds	O
constructed	O
with	O
the	O
dideoxy	B-PARTIUPAC
-	I-PARTIUPAC
L	I-PARTIUPAC
-	I-PARTIUPAC
erythro	I-PARTIUPAC
-	I-PARTIUPAC
or	O
-	B-PARTIUPAC
threo	I-PARTIUPAC
-	I-PARTIUPAC
hexono	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
lactone	I-PARTIUPAC
template	O
were	O
synthesized	O
stereospecifically	O
from	O
tri	B-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glucal	I-IUPAC
and	O
L	B-IUPAC
-	I-IUPAC
galactono	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
lactone	I-IUPAC
,	O
respectively	O
.	O
In	O
contrast	O
,	O
related	O
5	B-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
azirinyl	I-IUPAC
)	I-IUPAC
]	I-IUPAC
uracil	I-IUPAC
analogues	B-MODIFIER
(	O
10b	O
,	O
c	O
)	O
were	O
devoid	O
of	O
anti	O
-	O
DHBV	O
activity	O
,	O
indicating	O
that	O
an	O
acyclic	O
side	O
chain	O
at	O
C	O
-	O
5	O
position	O
of	O
the	O
pyrimidine	O
ring	O
is	O
essential	O
for	O
anti	O
-	O
HBV	O
activity	O
.	O
The	O
nature	O
of	O
the	O
substituent	O
introduced	O
in	O
the	O
7	O
-	O
position	O
as	O
well	O
as	O
the	O
nature	O
of	O
the	O
alkylamino	O
side	O
chain	O
in	O
the	O
3	O
-	O
position	O
strongly	O
affected	O
both	O
potency	O
and	O
tissue	O
selectivity	O
of	O
4H	B-IUPAC
-	I-IUPAC
1,2,4	I-IUPAC
-	I-IUPAC
benzothiadiazine	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dioxides	I-IUPAC
.	O
The	O
syn	O
/	O
anti	O
-	O
energy	O
barrier	O
for	O
these	O
nucleoside	O
analogues	O
is	O
5-6	O
kcal	O
/	O
mol	O
higher	O
than	O
for	O
common	O
nucleosides	O
.	O
Several	O
7	B-IUPAC
-	I-IUPAC
chloro	I-IUPAC
analogues	B-MODIFIER
,	O
12b	O
,	O
13b	O
.1	O
,	O
b	O
.2	O
,	O
and	O
14b	O
,	O
and	O
the	O
dimer	O
16b	O
have	O
been	O
prepared	O
and	O
evaluated	O
in	O
order	O
to	O
determine	O
the	O
optimum	O
lateral	O
chain	O
in	O
position	O
3	O
,	O
which	O
appears	O
to	O
be	O
the	O
[	B-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
moiety	B-MODIFIER
.	O
From	O
the	O
results	O
of	O
this	O
study	O
,	O
we	O
conclude	O
that	O
a	O
phenyl	O
group	O
situated	O
at	O
C	O
-	O
3	O
(	O
alpha	O
to	O
the	O
lactone	O
carbonyl	O
group	O
)	O
in	O
both	O
the	O
5	B-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodomethylidene	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
(	O
I	O
)	O
and	O
6	B-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
iodomethylidene	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyranone	I-IUPAC
(	O
II	O
)	O
series	O
is	O
essential	O
for	O
their	O
activity	O
as	O
mechanism	O
-	O
based	O
irreversible	O
inactivators	O
of	O
chymotrypsin	O
.	O
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
Hydroxystyryl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
DMPX	I-IUPAC
(	O
7	O
)	O
and	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
methoxystyryl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propargylxanthine	I-IUPAC
(	O
5e	O
,	O
MSX	O
-	O
2	O
)	O
were	O
the	O
most	O
potent	O
and	O
A	O
(	O
2A	O
)	O
-	O
selective	O
compounds	O
and	O
were	O
selected	O
for	O
prodrug	O
formation	O
.	O
These	O
analogues	O
are	O
1	O
,	O
d	O
-	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Ile4AVP	O
;	O
2	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Abu4AVP	O
;	O
3	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Thr4AVP	O
;	O
4	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Ala4AVP	O
;	O
5	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2AVP	O
;	O
6	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Lys4AVP	O
;	O
7	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Cha4AVP	O
;	O
8	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Nle4AVP	O
;	O
9	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Nva4AVP	O
;	O
10	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Phe4AVP	O
;	O
11	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Leu4AVP	O
;	O
12	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Gly4AVP	O
;	O
13	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Tyr4AVP	O
;	O
14	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Pro4AVP	O
.	O
The	O
most	O
active	O
compounds	O
synthesized	O
were	O
4	B-IUPAC
-	I-IUPAC
aminoisoquinoline	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
thiosemicarbazone	I-IUPAC
(	O
9a	O
)	O
and	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
methylamino	I-IUPAC
)	I-IUPAC
isoquinoline	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxaldehyde	I-IUPAC
thiosemicarbazone	I-IUPAC
(	O
9b	O
)	O
,	O
which	O
both	O
produced	O
optimum	O
%	O
T	O
/	O
C	O
values	O
of	O
177	O
against	O
the	O
L1210	O
leukemia	O
in	O
mice	O
when	O
used	O
at	O
a	O
daily	O
dosage	O
of	O
40	O
mg	O
/	O
kg	O
for	O
6	O
consecutive	O
days	O
.	O
The	O
trans	O
-	O
[	O
PtCl2	O
(	O
NH3	O
)	O
(	O
pip	O
-	O
pip	O
)	O
]	O
x	O
HCl	O
was	O
significantly	O
more	O
potent	O
than	O
cisplatin	O
in	O
all	O
the	O
cisplatin	O
-	O
resistant	O
ovarian	O
cancer	O
cell	O
lines	O
and	O
was	O
nearly	O
as	O
cytotoxic	O
as	O
cisplatin	O
against	O
colon	O
cancer	O
cells	O
.	O
The	O
effect	O
of	O
the	O
lead	O
compound	O
9h	O
on	O
K562	O
cell	O
growth	O
was	O
associated	O
with	O
cell	O
cycle	O
arrest	O
in	O
G2	O
/	O
M	O
.	O
Among	O
the	O
compound	O
synthesized	O
,	O
5	B-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
derivative	B-MODIFIER
29	O
was	O
found	O
to	O
exhibit	O
the	O
most	O
potent	O
anti	O
-	O
HIV	O
activity	O
(	O
EC50	O
=	O
0.0012	O
microM	O
)	O
although	O
it	O
was	O
toxic	O
(	O
IC50	O
=	O
10.0	O
microM	O
)	O
.	O
Additionally	O
,	O
we	O
reported	O
that	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
38	O
,	O
Glu30	O
,	O
DHis32	O
,	O
Lys33	O
]	O
hCRF	O
(	O
12-41	O
)	O
(	O
3	O
)	O
and	O
dicyclo	O
(	O
26-36,30-33	O
)	O
[	O
Ac	O
-	O
Asp9	O
,	O
DPhe12	O
,	O
Nle21	O
,	O
38	O
,	O
Cys26	O
,	O
Glu30	O
,	O
Lys33	O
,	O
Cys36	O
]	O
hCRF	O
(	O
9-41	O
)	O
were	O
ca.	O
twice	O
and	O
1/100	O
as	O
potent	O
as	O
astressin	O
,	O
respectively	O
,	O
suggesting	O
a	O
putative	O
turn	O
that	O
encompasses	O
residues	O
30-33	O
(	O
previous	O
paper	O
:	O
Koerber	O
et	O
al.	O
J	O
.	O
D	O
.	O
The	O
most	O
active	O
were	O
analogues	O
4c	O
,	O
4d	O
,	O
4e	O
,	O
and	O
6e	O
(	O
IC50	O
10-20	O
microM	O
)	O
.	O
This	O
compound	O
had	O
the	O
following	O
binding	O
affinities	O
:	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
16	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.27	O
nM	O
,	O
IC50	O
(	O
5	O
-	O
HT1A	O
)	O
=	O
22,000	O
nM	O
,	O
IC50	O
(	O
5	O
-	O
HT2A	O
)	O
=	O
270	O
nM	O
,	O
IC50	O
(	O
D2	O
)	O
=	O
4200	O
nM	O
,	O
IC50	O
(	O
alpha	O
1	O
)	O
=	O
220	O
nM	O
.	O
Novel	O
derivatives	O
of	O
benzo	B-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinolones	I-IUPAC
3a	O
-	O
j	O
were	O
synthesized	O
in	O
a	O
multistep	O
synthesis	O
starting	O
from	O
substituted	B-MODIFIER
benzo	B-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carbonyl	I-IUPAC
chlorides	I-IUPAC
,	O
to	O
their	O
corresponding	O
benzo	B-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thiophene	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
,	O
which	O
were	O
photochemically	O
dehydrohalogenated	O
to	O
their	O
corresponding	O
substituted	O
benzo	B-IUPAC
[	I-IUPAC
b	I-IUPAC
]	I-IUPAC
thieno	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinolones	I-IUPAC
.	O
To	O
enhance	O
the	O
intrinsic	O
potency	O
of	O
dihydropyrimidine	O
calcium	O
channel	O
blockers	O
,	O
we	O
have	O
modified	O
the	O
structure	O
of	O
previously	O
described	O
2	B-IUPAC
-	I-IUPAC
heteroalkyl	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydropyrimidines	I-IUPAC
2	O
to	O
3	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
1,4	B-IUPAC
-	I-IUPAC
dihydropyrimidines	I-IUPAC
3	O
.	O
In	O
addition	O
,	O
it	O
was	O
significantly	O
inhibitory	O
for	O
thymidine	O
kinase	O
deficient	O
strain	O
of	O
HSV	O
-	O
1	O
(	O
EC	O
(	O
50	O
)	O
=	O
2.3-15.3	O
microM	O
)	O
.	O
In	O
earlier	O
reports	O
we	O
identified	O
specific	O
point	O
substitutions	O
(	O
DPhe12	O
,	O
Nle21	O
,	O
38	O
)	O
,	O
cyclization	O
strategies	O
[	O
in	O
particular	O
,	O
introduction	O
of	O
lactam	O
rings	O
such	O
as	O
that	O
of	O
cyclo	O
(	O
Glu30	O
,	O
Lys33	O
)	O
]	O
,	O
and	O
deletions	O
(	O
residues	O
1-7	O
)	O
in	O
the	O
CRF	O
molecule	O
that	O
led	O
to	O
agonists	O
.	O
Ligands	O
were	O
administered	O
to	O
mice	O
[	O
30	O
mumol	O
kg	O
-	O
1	O
ip	O
at	O
1	O
h	O
or	O
orally	O
at	O
3	O
min	O
after	O
iv	O
injection	O
of	O
plutonium	O
(	O
IV	O
)	O
-	O
238	O
citrate	O
,	O
kill	O
at	O
24	O
h	O
]	O
.	O
The	O
structures	O
of	O
4	O
,	O
10	O
,	O
14	O
,	O
18	O
,	O
and	O
20	O
have	O
been	O
established	O
by	O
270	O
-	O
MHz	O
1H	O
NMR	O
spectroscopic	O
analyses	O
.	O
LDA	O
(	O
lithium	O
diisopropylamide	O
)	O
lithiation	O
of	O
5	B-IUPAC
-	I-IUPAC
ethyluracil	I-IUPAC
derivatives	B-MODIFIER
7	O
and	O
8	O
and	O
subsequent	O
reaction	O
with	O
an	O
aryl	O
aldehyde	O
gave	O
6	B-IUPAC
-	I-IUPAC
(	I-IUPAC
arylhydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ethyluracil	I-IUPAC
derivatives	B-MODIFIER
9-12	O
.	O
These	O
show	O
that	O
a	O
carbon	O
rather	O
than	O
a	O
nitrogen	O
atom	O
at	O
the	O
5	O
-	O
position	O
leads	O
to	O
significant	O
conformational	O
changes	O
in	O
the	O
molecule	O
(	O
a	O
longer	O
C5a	O
-	O
C4	O
bond	O
and	O
a	O
30	O
degrees	O
out	O
-	O
of	O
-	O
plane	O
rotation	O
of	O
the	O
phenyl	O
group	O
)	O
,	O
due	O
to	O
the	O
requirement	O
to	O
relieve	O
nonbonding	O
interactions	O
between	O
the	O
C5	O
and	O
N9	O
protons	O
.	O
Med.	O
Chem.	O
1996	O
,	O
39	O
,	O
781-788	O
)	O
.	O
The	O
phenyl	O
ring	O
appended	O
analogues	O
were	O
designed	O
to	O
specifically	O
interact	O
with	O
Phe69	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
from	O
Pneumocystis	O
carinii	O
(	O
pc	O
)	O
to	O
afford	O
selective	O
inhibitors	O
of	O
pcDHFR	O
.	O
However	O
,	O
as	O
expected	O
,	O
incubation	O
of	O
these	O
prodrugs	O
with	O
beta	O
-	O
glucuronidase	O
in	O
the	O
culture	O
medium	O
led	O
to	O
much	O
more	O
efficient	O
cell	O
killing	O
by	O
BCNU	O
as	O
a	O
result	O
of	O
the	O
liberation	O
of	O
the	O
more	O
potent	O
inactivators	O
,	O
O	B-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
and	O
O	B-IUPAC
(	I-IUPAC
6	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyguanosine	I-IUPAC
.	O
Experimentally	O
and	O
theoretically	O
,	O
the	O
n	B-IUPAC
-	I-IUPAC
propyl	I-IUPAC
group	B-MODIFIER
was	O
found	O
to	O
approximate	O
the	O
ideal	O
size	O
for	O
the	O
alkyl	O
group	O
in	O
both	O
the	O
5	O
and	O
7	O
positions	O
;	O
5,7	B-IUPAC
-	I-IUPAC
di	I-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
ethoxycarbonylpyrazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
5e	O
)	O
was	O
the	O
most	O
potent	O
inhibitor	O
of	O
both	O
lung	O
and	O
heart	O
PDE	O
.	O
Ring	O
annulation	O
was	O
achieved	O
with	O
methanolic	O
ammonia	O
affording	O
the	O
7	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
bromopyrrolo+	I-IUPAC
+	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
carbonitrile	I-IUPAC
derivatives	B-MODIFIER
3a	O
-	O
k	O
.	O
5	B-IUPAC
-	I-IUPAC
Fluoronorepinephrine	I-IUPAC
retains	O
both	O
beta	O
-	O
and	O
alpha	O
-	O
adrenergic	O
agonist	O
properties	O
.	O
Most	O
of	O
them	O
[	O
rac	O
-	O
27-31	O
,	O
(	O
-	O
)	O
-	O
28	O
,	O
and	O
(	O
-	O
)	O
-	O
30	O
]	O
,	O
which	O
are	O
more	O
active	O
than	O
(	O
-	O
)	O
-	O
huperzine	O
A	O
as	O
AChE	O
inhibitors	O
,	O
turned	O
out	O
to	O
be	O
quite	O
selective	O
for	O
AChE	O
,	O
although	O
not	O
so	O
selective	O
as	O
(	O
-	O
)	O
-	O
huperzine	O
A	O
.	O
An	O
N5	B-IUPAC
-	I-IUPAC
pivaloyl	I-IUPAC
derivative	B-MODIFIER
,	O
which	O
was	O
less	O
potent	O
than	O
27	O
at	O
A1	O
,	O
A2A	O
,	O
and	O
A3	O
receptors	O
,	O
retained	O
moderate	O
potency	O
at	O
A2B	O
receptors	O
.	O
Isoornithines	O
were	O
not	O
taken	O
up	O
by	O
H	O
-	O
35	O
hepatoma	O
cells	O
;	O
hence	O
they	O
did	O
not	O
affect	O
their	O
ODC	O
activity	O
.	O
New	O
acylated	O
bis	B-IUPAC
-	I-IUPAC
catecholates	I-IUPAC
and	O
1,3	B-IUPAC
-	I-IUPAC
benzoxazine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
derivatives	B-MODIFIER
based	O
on	O
secondary	O
diamino	O
acids	O
(	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
glycines	I-IUPAC
,	O
N	B-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
-	I-IUPAC
alanine	I-IUPAC
,	O
and	O
N	B-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminovaleric	I-IUPAC
acid	I-IUPAC
)	O
,	O
on	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
aminomethyl	I-IUPAC
benzoic	I-IUPAC
acids	I-IUPAC
,	O
on	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
aminoalkyl	I-IUPAC
)	I-IUPAC
aminomethyl	I-IUPAC
phenoxyacetic	I-IUPAC
acids	I-IUPAC
,	O
or	O
on	O
3,5	B-IUPAC
-	I-IUPAC
diaminobenzoic	I-IUPAC
acid	I-IUPAC
were	O
synthesized	O
as	O
artificial	O
siderophores	O
.	O
The	O
(	O
SS	O
)	O
-	O
and	O
(	O
SR	O
)	O
-	O
isomers	O
were	O
also	O
more	O
selective	O
on	O
cerebral	O
tissue	O
when	O
compared	O
with	O
ileal	O
and	O
cardiac	O
preparations	O
.	O
It	O
is	O
well	O
known	O
that	O
1	O
is	O
metabolized	O
to	O
its	O
phenolic	O
derivative	O
dextrorphan	O
(	O
2	O
)	O
and	O
this	O
metabolite	O
is	O
also	O
a	O
potent	O
anticonvulsant	O
.	O
Among	O
these	O
compounds	O
that	O
had	O
a	O
lower	O
activity	O
toward	O
sigma	O
binding	O
sites	O
,	O
a	O
high	O
5	O
-	O
HT1A	O
affinity	O
was	O
found	O
for	O
the	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylpropyl	I-IUPAC
)	I-IUPAC
derivative	B-MODIFIER
21	O
(	O
Ki	O
=	O
4.4	O
nM	O
)	O
which	O
demonstrated	O
very	O
good	O
selectivity	O
.	O
HCl	O
.	O
When	O
tested	O
for	O
their	O
antagonistic	O
activity	O
in	O
the	O
above	O
tissues	O
,	O
only	O
VII	O
and	O
VIII	O
were	O
found	O
to	O
inhibit	O
responses	O
to	O
angiotensin	O
II	O
.	O
The	O
synthesis	O
and	O
biological	O
activities	O
of	O
14	O
6	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
2,4	B-IUPAC
-	I-IUPAC
diaminoquinazolines	I-IUPAC
are	O
reported	O
.	O
When	O
3	O
was	O
given	O
ip	O
in	O
water	O
to	O
P388	O
leukemic	O
mice	O
at	O
400	O
mg	O
/	O
kg	O
(	O
b	O
.	O
Focused	O
libraries	O
incorporating	O
6	B-PARTIUPAC
-	I-PARTIUPAC
,	O
7	B-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
8	B-IUPAC
-	I-IUPAC
aryl	I-IUPAC
and	O
heteroaryl	B-IUPAC
substituents	B-MODIFIER
were	O
prepared	O
.	O
It	O
is	O
transported	O
into	O
the	O
tumor	O
cells	O
by	O
the	O
neuronal	O
norepinephrine	O
(	O
NE	O
)	O
transporter	O
(	O
NET	O
)	O
which	O
is	O
expressed	O
in	O
almost	O
all	O
neuroblastoma	O
cells	O
.	O
The	O
substitution	O
of	O
an	O
n	B-IUPAC
-	I-IUPAC
propyl	I-IUPAC
group	B-MODIFIER
with	O
different	O
alkylphenyl	O
groups	O
,	O
to	O
give	O
compounds	O
18b	O
-	O
e	O
,	O
increases	O
the	O
affinity	O
for	O
the	O
D	O
-	O
2	O
subtype	O
from	O
19	O
-	O
fold	O
to	O
36	O
-	O
fold	O
.	O
With	O
an	O
antiantidiuretic	O
"	O
effective	O
dose	O
"	O
of	O
0.46	O
+	O
/	O
-	O
0.07	O
nmol	O
/	O
kg	O
and	O
a	O
pA2	O
value	O
of	O
8.24	O
+	O
/	O
-	O
0.08	O
,	O
d	O
(	O
CH2	O
)	O
5	O
-	O
D	O
-	O
Phe2	O
,	O
Ile4AVP	O
(	O
1	O
)	O
appears	O
to	O
be	O
the	O
most	O
potent	O
antidiuretic	O
antagonist	O
reported	O
to	O
date	O
.	O
of	O
less	O
than	O
10	O
nM	O
.	O
Introduction	O
of	O
an	O
alkyl	O
substituent	O
in	O
the	O
5	O
-	O
position	O
of	O
the	O
thienyl	O
group	O
of	O
5	B-IUPAC
-	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
or	O
substitution	O
of	O
the	O
2	B-IUPAC
-	I-IUPAC
deoxyribofuranose	I-IUPAC
ring	B-MODIFIER
by	O
an	O
arabinofuranose	O
moiety	O
gave	O
decreased	O
activity	O
against	O
HSV	O
-	O
1	O
and	O
VZV	O
replication	O
when	O
compared	O
with	O
the	O
5	B-IUPAC
"	I-IUPAC
-	I-IUPAC
halogenated	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
thien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
.	O
In	O
a	O
preliminary	O
screening	O
,	O
several	O
of	O
these	O
compounds	O
have	O
demonstrated	O
significant	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
against	O
certain	O
DNA	O
and	O
RNA	O
viruses	O
in	O
vitro	O
,	O
as	O
well	O
as	O
moderate	O
activity	O
against	O
L1210	O
and	O
P388	O
leukemia	O
in	O
cell	O
culture	O
.	O
Little	O
or	O
no	O
activity	O
was	O
observed	O
against	O
a	O
range	O
of	O
other	O
DNA	O
and	O
RNA	O
viruses	O
.	O
Introduction	O
of	O
two	O
m	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
groups	B-MODIFIER
into	O
the	O
phenylthio	B-IUPAC
ring	B-MODIFIER
also	O
potentiated	O
the	O
activity	O
.	O
A	O
series	O
of	O
analogues	O
including	O
esters	O
of	O
ethanol	O
and	O
N	B-IUPAC
-	I-IUPAC
hydroxysuccinimide	I-IUPAC
,	O
amides	O
,	O
a	O
hydrazide	O
,	O
an	O
acylurea	O
,	O
and	O
anilides	O
were	O
prepared	O
.	O
The	O
most	O
potent	O
analogue	O
,	O
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
]	I-IUPAC
adenosine	I-IUPAC
19	O
,	O
has	O
an	O
EC50	O
for	O
coronary	O
vasodilation	O
of	O
190	O
pM	O
and	O
an	O
A1	O
/	O
A2	O
selectivity	O
ratio	O
of	O
44,000	O
.	O
4	B-IUPAC
-	I-IUPAC
Morpholino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
formylpyridine	I-IUPAC
thiosemicarbazone	I-IUPAC
was	O
the	O
most	O
active	O
antineoplastic	O
agent	O
of	O
this	O
series	O
in	O
mice	O
bearing	O
Sarcoma	O
180	O
ascites	O
cells	O
and	O
was	O
significantly	O
superior	O
to	O
5	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
formylpyridine	I-IUPAC
thiosemicarbazone	I-IUPAC
in	O
this	O
test	O
system	O
.	O
Crystallographic	O
data	O
for	O
the	O
ternary	O
complex	O
of	O
hDHFR	O
-	O
NADPH	O
and	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
,	O
1c	O
,	O
reveal	O
the	O
first	O
structural	O
details	O
for	O
a	O
reversed	O
N9	O
-	O
C10	O
folate	O
bridge	O
geometry	O
as	O
well	O
as	O
the	O
first	O
conformational	O
details	O
of	O
a	O
hybrid	O
piritrexim	O
-	O
trimetrexate	O
analogue	O
.	O
At	O
the	O
A2	O
receptor	O
2	B-IUPAC
-	I-IUPAC
phenethoxyadenosine	I-IUPAC
is	O
the	O
most	O
potent	O
of	O
the	O
2	B-IUPAC
-	I-IUPAC
phenylalkyladenosines	I-IUPAC
.	O
K	O
(	O
i	O
)	O
values	O
for	O
spermidine	O
uptake	O
were	O
also	O
determined	O
in	O
L1210	O
cells	O
.	O
Several	O
new	O
analogues	O
of	O
L	B-IUPAC
-	I-IUPAC
fucose	I-IUPAC
modified	O
in	O
the	O
2	O
position	O
and	O
the	O
5	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	B-MODIFIER
have	O
been	O
synthesized	O
as	O
potential	O
plasma	O
-	O
membrane	O
glycoconjugate	O
inhibitors	O
or	O
modifiers	O
,	O
and	O
their	O
biological	O
effects	O
have	O
been	O
studied	O
.	O
(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-	O
8	O
were	O
obtained	O
in	O
greater	O
than	O
98%	O
optical	O
purity	O
through	O
three	O
recrystallizations	O
from	O
ethanol	O
of	O
the	O
(	B-PARTIUPAC
S	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
+	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	B-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
mandelate	I-IUPAC
salts	I-IUPAC
of	O
intermediate	O
(	B-IUPAC
+	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
cis	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
bicyclo	I-IUPAC
[	I-IUPAC
3.1.0	I-IUPAC
]	I-IUPAC
hexylamine	I-IUPAC
(	O
[	O
(	O
+	O
/	O
-	O
)	O
-	O
16	O
]	O
.	O
These	O
compounds	O
were	O
found	O
to	O
be	O
active	O
in	O
vitro	O
for	O
LTC4	O
/	O
D4	O
inhibition	O
with	O
the	O
potencies	O
(	O
IC50	O
's	O
)	O
ranging	O
from	O
0.2	O
to	O
85	O
microM	O
.	O
Analogues	O
6b	O
,	O
d	O
-	O
h	O
and	O
5	O
-	O
hydroxymethyl	O
-	O
dUMP	O
,	O
similar	O
to	O
N	O
(	O
4	O
)	O
-	O
hydroxy	O
-	O
dCMP	O
(	O
6a	O
)	O
and	O
FdUMP	O
,	O
were	O
also	O
N	O
(	O
5	O
)	O
,	O
N	B-IUPAC
(	I-IUPAC
10	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylenetetrahydrofolate	I-IUPAC
-	O
dependent	O
,	O
hence	O
mechanism	O
-	O
based	O
,	O
slow	O
-	O
binding	O
inhibitors	O
.	O
In	O
contrast	O
,	O
2a	O
,	O
3a	O
,	O
and	O
3b	O
induced	O
differentiation	O
of	O
only	O
a	O
very	O
small	O
percentage	O
of	O
the	O
cells	O
.	O
The	O
best	O
inhibitors	O
for	O
calpain	O
II	O
were	O
Z	O
-	O
Leu	O
-	O
Abu	O
-	O
CONH	O
-	O
CH2	O
-	O
CHOH	O
-	O
C6H5	O
(	O
Ki	O
=	O
15	O
nM	O
)	O
,	O
Z	O
-	O
Leu	O
-	O
Abu	O
-	O
CONH	O
-	O
CH2	O
-	O
2	O
-	O
pyridyl	O
(	O
Ki	O
=	O
17	O
nM	O
)	O
,	O
and	O
Z	O
-	O
Leu	O
-	O
Abu	O
-	O
CONH	O
-	O
CH2	O
-	O
C6H3	O
(	O
3,5	O
(	O
OMe	O
)	O
2	O
)	O
(	O
Ki	O
=	O
22	O
nM	O
)	O
.	O
The	O
indolin	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
imidazoline	I-IUPAC
4b	O
was	O
found	O
to	O
possess	O
potent	O
alpha	O
2	O
-	O
adrenergic	O
agonist	O
and	O
antagonist	O
activity	O
.	O
A	O
series	O
of	O
straight	O
chain	O
alkyl	O
amides	O
demonstrated	O
that	O
the	O
optimal	O
chain	O
length	O
occurs	O
with	O
the	O
5	B-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
propionyl	I-IUPAC
derivative	B-MODIFIER
,	O
3	O
,	O
which	O
had	O
a	O
Ki	O
value	O
of	O
7.7	O
nM	O
at	O
human	O
A3	O
receptors	O
,	O
and	O
was	O
40	O
-	O
and	O
14	O
-	O
fold	O
selective	O
vs	O
rat	O
A1	O
and	O
A2A	O
receptors	O
,	O
respectively	O
.	O
Additionally	O
methyl	B-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoate	I-IUPAC
(	O
2d	O
)	O
,	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoic	I-IUPAC
acid	I-IUPAC
(	O
3d	O
)	O
,	O
methyl	B-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoate	I-IUPAC
(	O
2f	O
)	O
,	O
and	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxobut	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
enoic	I-IUPAC
acid	I-IUPAC
(	O
3f	O
)	O
prevent	O
the	O
increase	O
in	O
the	O
interferon	O
-	O
gamma	O
-	O
induced	O
synthesis	O
of	O
quinolinic	O
acid	O
in	O
primary	O
cultures	O
of	O
cultured	O
human	O
peripheral	O
blood	O
monocyte	O
-	O
derived	O
macrophages	O
.	O
C	O
.	O
The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
for	O
our	O
synthetic	O
[	O
111In	O
]	O
DTPA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
was	O
4.31	O
nM	O
,	O
which	O
is	O
comparable	O
to	O
a	O
Kd	O
=	O
5.57	O
nM	O
obtained	O
with	O
commercially	O
available	O
DTPA	O
-	O
D	O
-	O
Phe1	O
-	O
octreotide	O
.	O
More	O
significantly	O
,	O
some	O
piperazines	O
derivatives	O
of	O
[	B-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
a	I-IUPAC
]	I-IUPAC
triazine	I-IUPAC
also	O
possessed	O
good	O
oral	O
efficacy	O
in	O
rodent	O
models	O
of	O
Parkinson	O
's	O
disease	O
.	O
Compound	O
6	O
thus	O
represents	O
a	O
new	O
structural	O
class	O
of	O
GluR5	O
agonists	O
.	O
Two	O
syntheses	O
have	O
been	O
elaborated	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
represented	O
by	O
the	O
general	O
formulas	O
II	O
-	O
V	O
where	O
R1	O
=	O
hydrogen	O
,	O
halogen	O
,	O
or	O
methyl	B-IUPAC
;	O
Y	O
=	O
CONHR	O
,	O
OCOR	O
,	O
or	O
CO	O
(	O
CH2	O
)	O
nNHR	O
,	O
in	O
which	O
R	O
=	O
alkyl	O
or	O
aralkyl	O
or	O
NHR	O
=	O
cyclic	O
amine	O
and	O
n	O
=	O
1-2	O
.	O
Compound	O
1	O
also	O
displayed	O
significant	O
activity	O
against	O
rhinovirus	O
type	O
34	O
.	O
The	O
latter	O
derivatives	O
were	O
also	O
more	O
effective	O
than	O
O6	B-IUPAC
-	I-IUPAC
benzylguanine	I-IUPAC
at	O
inactivating	O
AGT	O
in	O
intact	O
HT29	O
colon	O
tumor	O
cells	O
.	O
The	O
CoMSIA	O
models	O
displayed	O
r	O
(	O
2	O
)	O
(	O
cv	O
)	O
0.663-0.729	O
,	O
r	O
(	O
2	O
)	O
(	O
ncv	O
)	O
0.909-0.998	O
,	O
r	O
(	O
2	O
)	O
(	O
pred	O
)	O
0.554-0.855	O
.	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Bromothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
caused	O
prompt	O
healing	O
of	O
HSV	O
-	O
1	O
keratitis	O
when	O
administered	O
as	O
eye	O
drops	O
(	O
0.2%	O
)	O
to	O
rabbits	O
.	O
Similar	O
glycosylations	O
of	O
3	B-IUPAC
-	I-IUPAC
cyanoallopurinol	I-IUPAC
and	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
allopurinol	I-IUPAC
furnished	O
the	O
corresponding	O
protected	O
N	B-IUPAC
-	I-IUPAC
1	I-IUPAC
glycosyl	I-IUPAC
derivatives	B-MODIFIER
(	O
5b	O
and	O
5c	O
)	O
.	O
The	O
metabolic	O
study	O
using	O
isolated	O
Langendorff	O
perfused	O
rat	O
hearts	O
demonstrated	O
that	O
approximately	O
67%	O
of	O
perfused	O
[	O
99mTc	O
]	O
CpTT	O
-	O
PA	O
was	O
incorporated	O
and	O
[	O
99mTc	O
]	O
CpTT	O
-	O
propionic	O
acid	O
,	O
the	O
metabolite	O
after	O
six	O
cycles	O
of	O
beta	O
-	O
oxidation	O
of	O
[	O
99mTc	O
]	O
CpTT	O
-	O
PA	O
,	O
was	O
detected	O
as	O
the	O
major	O
radiometabolite	O
in	O
the	O
perfusate	O
and	O
myocardium	O
.	O
Synthetic	O
routes	O
to	O
the	O
heretofore	O
unknown	O
ylidenemalononitriles	O
,	O
and	O
the	O
ketone	O
precursors	O
thereof	O
,	O
were	O
developed	O
.	O
In	O
particular	O
,	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1,2,5,6	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
pyridinyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
thiazolamine	I-IUPAC
(	O
4c	O
,	O
PD	O
118440	O
)	O
and	O
its	O
allyl	B-IUPAC
analogue	B-MODIFIER
(	O
4i	O
,	O
PD	O
120697	O
)	O
have	O
been	O
identified	O
as	O
orally	O
active	O
dopamine	O
(	O
DA	O
)	O
agonists	O
with	O
pronounced	O
central	O
nervous	O
system	O
effects	O
in	O
tests	O
that	O
include	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
haloperidol	I-IUPAC
and	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
propylnorapomorphine	I-IUPAC
binding	O
,	O
inhibition	O
of	O
striatal	O
DA	O
synthesis	O
,	O
inhibition	O
of	O
DA	O
neuronal	O
firing	O
,	O
inhibition	O
of	O
spontaneous	O
locomotor	O
activity	O
,	O
and	O
reversal	O
of	O
reserpine	O
-	O
induced	O
depression	O
in	O
rats	O
.	O
Also	O
,	O
the	O
activity	O
of	O
some	O
of	O
these	O
compounds	O
inhibiting	O
butyrylcholinesterase	B-IUPAC
(	O
BChE	O
)	O
was	O
tested	O
.	O
In	O
mediated	O
influx	O
into	O
L1210	O
cells	O
,	O
5	O
and	O
6	O
were	O
transported	O
2.7	O
-	O
and	O
8.5	O
-	O
fold	O
,	O
respectively	O
,	O
more	O
readily	O
than	O
MTX	O
.	O
To	O
further	O
elucidate	O
the	O
binding	O
requirements	O
for	O
this	O
site	O
,	O
we	O
synthesized	O
several	O
hydantoin	O
analogs	O
and	O
evaluated	O
these	O
in	O
in	O
vitro	O
sodium	O
channel	O
-	O
binding	O
and	O
/	O
or	O
in	O
vivo	O
whole	O
animal	O
anticonvulsant	O
assays	O
.	O
Compound	O
10	O
was	O
also	O
the	O
best	O
inhibitor	O
of	O
T	O
.	O
The	O
SARs	O
developed	O
from	O
the	O
new	O
compounds	O
,	O
together	O
with	O
those	O
collected	O
from	O
our	O
previous	O
studies	O
,	O
confirmed	O
the	O
hypothesis	O
of	O
different	O
binding	O
modes	O
for	O
5	O
-	O
substituted	O
and	O
5	O
-	O
unsubstituted	O
indoles	O
,	O
suggesting	O
that	O
the	O
shape	O
of	O
the	O
lipophilic	O
pocket	O
L	O
(	O
1	O
)	O
(	O
notation	O
in	O
accordance	O
with	O
Cook	O
's	O
BzR	O
topological	O
model	O
)	O
is	O
asymmetric	O
and	O
highlighted	O
the	O
stereoelectronic	O
and	O
conformational	O
properties	O
of	O
the	O
amide	O
side	O
chain	O
required	O
for	O
high	O
potency	O
.	O
New	O
siderophore	O
penicillin	O
V	O
conjugates	O
with	O
the	O
siderophore	O
component	O
attached	O
to	O
the	O
phenyl	O
ring	O
of	O
penicillin	O
V	O
are	O
inactive	O
against	O
these	O
Gram	O
-	O
negative	O
bacteria	O
.	O
